ERA-NET: Aligning national/regional translational cancer research programmes and activities

TRANSCAN-2

Joint Transnational Call for Proposals 2017 (JTC 2017):

“Translational research on rare cancers”

Call Text

Submission deadline for pre-proposals:

6th February 2018 at 16:00 (CET)

Electronic proposal submission system: http://transcan.cbim.it/
(Online submission will be possible from 5th December 2017)

For further information, please contact the Joint Call Secretariat (JCS) at:

Alliance Against Cancer (ACC)

E-mail: transcan-jtc2017@allianceagainstcancer.org

Mariangela Siler

Phone: +39 06 4990 6077
1. MOTIVATION ................................................................................................................ 3
2. AIMS OF THE CALL ..................................................................................................... 5
  2.1 Scientific project ........................................................................................................ 5
  2.2 Capacity building activities ....................................................................................... 7
3. CALL IMPLEMENTATION BOARDS ............................................................................ 8
4. APPLICATION ............................................................................................................... 8
  4.1 Eligibility criteria ...................................................................................................... 8
  4.2 Submission of joint proposals ................................................................................... 10
5. EVALUATION ............................................................................................................. 11
  5.1 Evaluation criteria ...................................................................................................... 11
  5.2 Scoring ...................................................................................................................... 12
  5.2.1 Range and interpretation of the scores .................................................................. 12
  5.2.2 Thresholds and weighting .................................................................................... 12
  5.3 Eligibility check of pre-proposals and first step of evaluation ................................. 13
  5.3.1 Eligibility check .................................................................................................... 13
  5.3.2 Evaluation of pre-proposals .................................................................................. 13
  5.4 Eligibility check of full proposals and second step of evaluation .......................... 13
  5.5 Funding decision ..................................................................................................... 14
6. FINANCIAL AND LEGAL ISSUES ............................................................................. 15
  6.1 Funding model and funding details .......................................................................... 15
  6.2 Research Consortium Agreement, ownership of intellectual property rights, ethical
      issues ........................................................................................................................ 15
  6.3 Confidentiality of proposals ..................................................................................... 16
7. REPORTING AND DISSEMINATION ......................................................................... 16
8. CONTACT AND FURTHER INFORMATION ................................................................. 17

ANNEX 1. CONTACT INFORMATION OF THE NATIONAL/REGIONAL FUNDING
ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2017 .................................. 18

ANNEX 2. INDICATIVE FUNDING COMMITMENT OF THE FUNDING ORGANISATIONS
PARTICIPATING IN TRANSCAN-2 JTC 2017 ................................................................. 24

ANNEX 3. ELIGIBILITY OF BENEFICIARY INSTITUTIONS FOR THE FUNDING
ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2017 ................................. 26

ANNEX 4. NATIONAL/REGIONAL REGULATIONS AND CONTACT INFORMATION .... 29
Rare cancers are traditionally defined on the basis of epidemiologic statistics. Incidence, i.e., the number of newly diagnosed cases of a given disease per 100,000 persons per year (100,000/year), has been consistently identified as the most efficient indicator for rare cancer definition. In this regard, at the European level, an operational definition of rare cancers based on cancer registry data has been provided and adopted within the RARECARE project, an initiative focused on the surveillance of rare cancers in Europe (http://www.rarecare.eu/). Accordingly, rare cancers are identified as diseases whose incidence, when individually considered, is lower than 6 newly diagnosed cases per 100,000/year in Europe. It is noteworthy that, if collectively considered, the 198 cancers identified by the RARECARE project represent the 22% of all newly diagnosed cancers in European countries each year, including rare adult solid tumors, rare hematologic cancers, and pediatric cancers (For the list of rare cancers, please visit the following link: http://www.ecpc.org/Documents/Projects/RARECAREnet/RARECAREnet_list_of_rare_cancers.xlsx).

When considering prevalence, the overall estimates raise to about 25%, which translates in about 4 millions of European people currently living with a diagnosis of rare cancer. In addition, survival rates for rare cancers are worse than for common cancers (47% versus 65%, respectively).

The diagnostic and therapeutic management of patients with rare cancers may pose particularly difficult challenges mainly related to the small numbers of patients diagnosed with the diseases of interest and difficulties in referring to large centers with multidisciplinary expertise. Independently on the study design of choice, the low incidence of these diseases tends to significantly constrain the ability of performing studies with adequate statistical power. In addition, in rare cancers, the pressing issue of the inherently low numbers inevitably and largely translates into a limited availability of high quality, clinically annotated, bio-specimen samples and, consequently, a dramatic impairment in the ability to explore the underlying molecular mechanisms of rare cancers. The aforementioned limitations have an enormous negative impact on the number of treatments which have the potential to significantly affect patients’ outcomes. Such limitations may be efficaciously contained and significantly minimized by the development of transnational networks, which may serve as an effective strategy for generating high quality and rigorous scientific evidence concerning rare cancers. The creation and implementation of functional networks among the collaborating partners involved at an international level would undoubtedly enhance the translational research potentials of each of the institutions involved. Translational networks may allow the conduct of projects fostering the use of multimodal treatments involving conventional and targeted approaches, drugs successfully used in other neoplasms that may find application in rare tumors, orphan drugs and, most interestingly, novel drugs that may be applied to multiple rare diseases, making them appealing and economically sustainable.
International consortia with a focus on translational research in rare cancers hold great potential in promoting multidisciplinary collaborations that in turn can speed the rate at which pre-clinical research discoveries become clinically viable health technologies and interventions. Among the most timely and largely unexplored topics potentially relevant to a translational research agenda, the role played by environmental determinants, ethnic variation and racial disparities in rare cancers may exemplify potential issues to be efficiently addressed throughout a network-based approach.

The national/regional funding organisations listed below have agreed to participate in the TRANSCAN-2 Joint Transnational Call for proposals 2017 (JTC 2017):

- Austrian Science Fund (FWF), Austria
- Research Foundation - Flanders (FWO), Belgium, Flanders
- Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, French speaking community
- Estonian Research Council (ETAg), Estonia
- National Cancer Institute (INCa), France
- ARC French Foundation for Cancer Research (ARC Foundation), France
- Federal Ministry of Education and Research (BMBF), Germany
- General Secretariat for Research & Technology (GSRT), Greece
- The Chief Scientist Office in the Ministry of Health (CSO-MOH), Israel
- Ministry of Health (MoH), Italy
- Alliance Against Cancer (ACC), Italy
- Lombardy Foundation for Biomedical Research (FRRB), Italy
- State Education Development Agency (VIAS), Latvia
- Luxembourg National Research Fund (FNR), Luxembourg
- Dutch Cancer Society (DCS), Netherlands
- National Centre for Research and Development (NCBR), Poland
- Foundation for Science and Technology (FCT), Portugal
- Slovak Academy of Sciences (SAS), Slovakia
- Spanish Association Against Cancer Scientific Foundation (FCAECC), Spain
- National Institute of Health Carlos III (ISCIII), Spain
- The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT), Spain
- Ministry of Science and Technology (MoST), Taiwan
- Scientific and Technological Research Council (TUBITAK), Turkey
2. AIMS OF THE CALL

2.1 Scientific project

The projects proposed within the TRANSCAN-2 JTC 2017 call must address the following topic:

“Translational research on rare cancers”

The decisions concerning the focus of the present call are strongly motivated by the challenges related to research and treatment in rare cancers, which are intimately tightened to the low incidence of any single clinical-pathological entity currently listed among these cancers. On this basis, a network-based approach within the operating framework provided by TRANSCAN-2 could contribute to address compelling research questions in the area of interest. Indeed, the development and consolidation of consortia founded on international collaborations will allow to efficiently integrate resources spanning the entire continuum from diagnostics to therapeutics and maximize the efforts for collecting clinically annotated biological samples. Such consortia will serve as a guide to pool scientific expertise, share novel insights and eventually train young investigators. In this view, the proposals of the present call will have to cover a minimum of one of the specific aims reported below, and within the aim/s of choice, the applicants will have to address at least one of the topics listed as bullet points. Proposals addressing one single aim and one single bullet point within the chosen aim will be allowed.

Aim 1: Design and conduct of translational research studies exploiting/combining resources from current clinical trials, bio-repositories and epidemiology-type resources.

Translational cancer research on aetiology, pathogenesis and prognosis of rare cancers is tightly linked to the integrated use and facilitated access to biospecimens from patients. Translational research goals in rare cancers may thus be achieved throughout studies of cohorts of patients with available biospecimens adequately stored in biorepositories linked to cancer registry data.

- Translational studies based on the analysis of data and/or of clinically annotated specimens from previously conducted/ongoing trials with adequate follow up.
- Conduct of studies for cancer risk assessment in rare cancers leveraging upon access to institutional and/or national cancer registries.
- Identification and characterization of the etiopathogenetic determinants involved in rare cancers aiming at increasing our knowledge of the underlying pathways to be targeted by means of existing or experimental therapies.
Aim 2: Development and exploitation of translational research platforms (e.g., patient derived xenograft models/organoids/tissue collections) to study drug responses/resistance and toxicity, and perform drug screens or repurpose approved anticancer drugs.

- Tissue collection, and genetic and epigenetic characterization of patient-derived rare tumors xenografts (PDXs). PDX could be used to identify determinants of heterogeneity in patient response to therapy, and thus inform patient-oriented therapeutic decisions. PDX could be used to screen for candidate pathways and/or therapeutics.
- Three-dimensional cultures (or 'organoids') obtained from patients’ rare tumors which closely replicate key properties of the original cancers. Organoid cultures could be amenable to the detection of genetic and/or epigenetic changes associated with drug sensitivity and may thus lead the way to targeted approaches that could improve clinical outcomes in cancer patients.
- Other translational research platforms that give insights into the drug responses/resistance and toxicity of drugs, and help perform drug screening for the treatment of rare diseases (e.g., induced pluripotent cell clones established from patient tumors and normal cells and induced to differentiate in vitro).

AIM 3: Implementation of precision biomarkers for better stratification of the clinical cohorts.

- Validation and implementation of rare cancers associated biomarkers as molecular predictors of therapeutic response, treatment resistance and disease outcome.
- Use of innovative, high throughput technologies designed to facilitate the comprehensive ‘omic assessment of genomes, transcriptomes, proteomes, metabolomes, etc. of patients affected by rare cancers.
- Design and conduct of phase I and/or phase II clinical studies aiming at the validation and implementation of precision biomarkers (including approaches based on liquid biopsies to enable non-invasive assessment of tumour heterogeneity and to monitor tumour dynamics) in patients diagnosed with rare cancers.

Inclusive criteria:

1. Rare cancers. This criterion will be applied to each of the proposals submitted for evaluation. Rare cancers will be defined as diseases whose incidence, when individually considered, is lower than 6 newly diagnosed cases per 100,000/year in Europe.
The RARECAREnet cancer list is available at the following link: [http://www.ecpc.org/Documents/Projects/RARECAREnet/RARECAREnet_list_of_rare_cancers.xlsx](http://www.ecpc.org/Documents/Projects/RARECAREnet/RARECAREnet_list_of_rare_cancers.xlsx)


The following types of research projects are excluded from the call:

1. Studies on common cancers, i.e., cancers whose incidence is equal to/greater than 6 newly diagnosed cases per 100,000/year.
2. Studies on biomarker discovery only.
3. Studies based on preclinical models only (e.g., transformed cell lines and animal models).
4. Phase III and IV clinical trials.

2.2 Capacity building activities

Translational research has the ambition to remove barriers to multidisciplinary collaboration. It is envisioned that clinicians, researchers and the operational staff from various sectors (academia, industry, regulatory bodies) will effectively work together to expedite the translation of scientific discoveries to clinical application and to more rapidly fuel research directions with observational or clinical findings. In fact, the complexity of the process requires, at the individual and collective levels, the creation of translational medicine research interfaces/infrastructures.

To reach that goal, TRANSCAN-2 supports capacity building activities for promoting the formation and upgrading of multidisciplinary teams in an integrated process: i) exchange/mobility of individual researchers/professionals within the consortium in order to bring new expertise to an existing multidisciplinary translational team, and/or ii) recruitment of individual researchers/professionals by a translational research team in order to cover expertise and “knowhow” unavailable in the existing team. This type of activities, when present, will be supported within the projects which will be selected for funding under TRANSCAN-2 JTC 2017. Thus, applicants may add an additional part to cover these activities (with an associated separate budget, in compliance with the rules of the respective national/regional funding organisations).
These capacity building activities have to be fully coherent with the objectives of the research project, and aimed to strengthening the ability of participating team(s) to perform the work detailed in the project plan as well as to improve, in the long term, the quality and potential of the translational research performed by the team(s). Depending on the project these activities could be (the following examples are indicative only, and neither exhaustive nor prescriptive): 1) exchanges/mobility of investigators (especially young investigators) between teams and countries participating in the project, 2) short term training of scientists, operational staff, etc., 3) training technical workshop dedicated to relevant aspects of the scientific work planned in the project, 4) short training (1 or few weeks) of several partner teams by one expert, etc. Activities related to the dissemination of results such as hosting a symposium, conferences etc. are out of the scope of this capacity building activities component.

3. CALL IMPLEMENTATION BOARDS

The Call Steering Committee (CSC) and the Scientific Evaluation Committee (SEC) will manage the evaluation procedure of pre-proposals and full proposals and the final selection of research projects, with the support of the Joint Call Secretariat (JCS).

The CSC is composed of one single representative from each national/regional funding organisation participating in TRANSCAN-2 JTC 2017. The CSC will supervise the preparation and the implementation of the call and will take all decisions concerning the call. Based on the ranking list established by the SEC, the CSC will take the final decision on the proposals to be funded. Members of the CSC are not allowed to submit proposals to this call.

The SEC is a panel of internationally recognised scientific experts in charge of the evaluation of submitted pre- and full proposals. SEC members are not allowed to submit or participate in proposals within this call. SEC members must sign declarations on conflicts of interest and confidentiality. In the second step of evaluation (full proposals stage), in addition to the SEC members, external peer reviewers chosen for their knowledge in specific fields covered by the proposals will also contribute to the evaluation.

4. APPLICATION

4.1 Eligibility criteria

Joint transnational research proposals may be submitted by applicants belonging to one of the following categories depending on national/regional eligibility rules as specified in Annex 3:

- Academic research groups (from universities or other higher education or research institutions).
- Clinical/public health sector research groups (from hospitals/public health and/or
other health care settings and health organisations).

- Enterprise’s research groups (depending on national/regional eligibility rules), with particular emphasis on small and medium-sized enterprises.

Only transnational projects will be funded. Each research consortium asking for funding must involve a minimum of three (3) research groups and a maximum of seven (7) research groups. The maximum number of 7 research groups could be increased only with partners from the following countries: Estonia, Latvia, Slovakia and Turkey, up to a maximum of 4 additional partners from the 4 countries, to reach a maximum total of 11 research groups in a proposal. In each consortium, groups applying for funding must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from one country (in such cases the minimum number of groups must be 4, coming from 3 different countries).

In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Estonia, Latvia, Slovakia and Turkey. A consortium may include one (1) research group (included in the maximum number of seven) with own funding from a country/region not partner in this call. This group must provide a written confirmation that its funding is already secured at the stage of the pre-proposal submission.

Each consortium must nominate a coordinator. The coordinator will be responsible for the scientific management (such as controlling, reporting, intellectual property rights issues, etc.) and will act as the interface with the JCS and the CSC. Each research team will be represented by one principal investigator only, who will be the contact person for the respective national/regional funding organisation.

Each consortium must involve at least one basic or pre-clinical research team and one clinical team. It is also recommended to include an expert team in methodology, biostatistics or bioinformatics, depending on the type of work planned. Consortia may also involve other teams with specialised skills and know-how (biobanks, model systems, technological platforms, etc.) or expertise (epidemiology and molecular epidemiology, early phase clinical trials, public health, ELSI, etc.). Consortia should have sufficient critical mass to achieve ambitious scientific, technological and medical goals and, along with the particular contribution of each research team, should clearly demonstrate its translational added value. The translational nature of the research results is the key goal of TRANSCAN-2 and, therefore, each consortium should also clearly demonstrate a knowledge transfer towards clinical, public health and/or industrial applications.

While the application will be submitted by the coordinator, the individual research groups will be funded by the funding organisation from their country/region that is participating in the
TRANSCAN-2 JTC 2017. The applications are therefore subject to eligibility criteria of national/regional funding organisations.

The inclusion of a non-eligible partner in a proposal may lead to the rejection of the entire proposal without further review. Prior to submitting a proposal, applicants should take note of individual national/regional rules described in the Annex 4 of this document in order to verify their eligibility, the eligible costs and potential budget available. Therefore, applicants are strongly advised to contact their national/regional funding organisations (see Annex 1. Contact information of the national/regional funding organisations) for any clarification.

Please note that an eligibility check before the pre-proposal submission is mandatory for the Ministry of Health (MoH), Italy, Alliance Againsts Cancer (ACC), Italy, Lombardy Foundation for Biomedical Research (FRRB), Italy. Participants from Turkey should also submit their proposals in Turkish to TUBITAK electronically via ardeb-pbs.tubitak.gov.tr by 12th of February for pre-proposals and no later than 5th of June for the full proposal stage.

The duration of the projects shall not exceed three (3) years. According to the eligibility criteria of the funding organisations contributing to the TRANSCAN-2 JTC 2017, a research group may however receive funding for less than three years.

4.2 Submission of joint proposals

TRANSCAN-2 JTC 2017 will be implemented through a two-stage submission procedure: pre-proposals and full proposals. Both pre- and full proposals must be written in English and must be submitted to the JCS by the coordinator through the electronic submission system exclusively.

In preparing the proposals, applicants should strictly follow the rules described in this call text and in the document entitled “Guidelines for applicants”, and use the application forms available from the electronic submission system (http://transcan.cbim.it/). Applicants should take note of individual national/regional rules, and contact their national/regional contact points for specific questions.

The pre-proposals must be submitted to the electronic submission system no later than the 6th of February 2018, at 16:00 (Central European Time, CET). The information relating to the selected pre-proposal will be communicated by the JCS to the coordinators by April 2018.

The information provided in the pre-proposal application is binding for the entire application process. Thus, any substantial changes between the pre-proposal and the full proposal (e.g. composition of the consortia, objectives of the project, etc.) must be communicated in advance to the JCS with detailed justification and will only be allowed by the CSC under exceptional circumstances.
The full proposals will have to be submitted to the electronic submission system not later than the 30th of May 2018 at 16:00 (Central European Summer Time, CEST). Please note that full proposals will only be accepted from applicants explicitly invited by the JCS to submit them.

The decision on the results of the full proposals evaluation meeting will be communicated to all the (successful and unsuccessful) coordinators in October 2018. The coordinators of the full proposals will receive a summary of the evaluation conclusions in due time.

5. EVALUATION

5.1 Evaluation criteria

Pre-proposals and full proposals will be assessed according to the following criteria.

1. Excellence

a. Scientific quality of the proposal: soundness of the rationale including transdisciplinary considerations, clarity of the objectives, expected progress beyond the state-of-the-art, international competitiveness.

b. Relevance of the project regarding the topic (translational research on rare cancers) and the overall objective (translational cancer research) of the call; availability and quality of preliminary data.

2. Impact

a. Potential impact with reference to the development, dissemination and use of project results: potential impact of the expected results on cancer control, in terms of translation into public health or clinical practices (enhancing innovation capacity and integration of new knowledge) and/or into pharmaceutical/industrial applications; appropriateness of measures for the dissemination and/or exploitation of project results including socio-economic aspects and anticipation of intellectual property issues (patenting, industrial exploitation, marketing, etc.).

b. Impact with reference to strengthening the translational capacity building activities:

This sub-criterion will be assessed at the level of the full proposal only and solely for the scientific proposals recommended for funding.

The assessment of the capacity building component and associated budget will be performed under this sub-criterion after the scientific assessment of the proposal: hence, a proposal could be recommended for funding without the part related to capacity building activities if this part is evaluated as “poor”.

The assessment under this sub-criterion will be performed independently using the following:

• Content: relevance and coherence of the capacity building activities with the proposal objectives.

• Candidate: background (scientific, medical, etc.), coherence with the CV, scientific production.
• Host team: expertise of the host team in the field, research qualification of the responsible person.

3. Quality and efficiency of the implementation

a. Coherence and effectiveness of the work plan: appropriateness and feasibility of the methodology (including the clinical trial if applicable) and associated technologies used, with particular regard to the study design, the study population(s), study endpoints.

b. Statistical/bio-statistical aspects and power calculation (including the clinical trial if applicable): study design; sampling calculations; appropriateness and robustness of statistical analyses: adequateness of endpoints.

c. Quality of the transnational research consortium: experience of the research partners in the field(s) of the proposal (for young teams: appropriateness of their current work and training of their members); quality of the collaboration between the research teams and added value of the research consortium as a whole.

d. Appropriateness of the management structures and procedures, including risk and innovation management.

e. Appropriateness of the allocation of tasks and resources to be committed (personnel, equipment, etc.) and of the estimated budget.

f. Compliance with ethical rules and regulatory aspects.

5.2 Scoring

5.2.1 Range and interpretation of the scores

A scoring system from 0 to 5 will be used to evaluate the proposals performance with respect to each evaluation criterion, as follows:

0: fails to address the criterion or missing information;
1: criterion poorly addressed/serious weaknesses;
2: fair/ some weaknesses;
3: good/ shortcomings are present;
4: very good/ criterion well addressed;
5: excellent.

Please note that half marks may be given.

5.2.2 Thresholds and weighting

The threshold for individual criteria is 3. The overall threshold, applying to the sum of the individual scores, is 10.

To determine the ranking:

- the score of the criterion "impact" will be given a weight of 1.5.
In case of equal score, the “impact” score will be considered first, then the score of “excellence” and then of “quality and efficiency of the implementation”.

5.3 Eligibility check of pre-proposals and first step of evaluation

5.3.1 Eligibility check

The JCS will examine all pre-proposals to ensure that they meet the call’s formal criteria (date of submission, number of participating partners, and countries/regions of provenience, inclusion of all necessary information in English, adherence to the application forms, document length). The JCS will forward the pre-proposals to the national/regional funding organizations, which will perform a formal check of compliance with their respective regulations.

After completion of the eligibility check, the CSC will take the final decision; the pre-proposals not considered eligible will be rejected without further review. The coordinators of the non-eligible pre-proposals will be informed accordingly by the JCS.

5.3.2 Evaluation of pre-proposals

Pre-proposals passing the formal eligibility checks will be reviewed by the SEC panel. All necessary steps will be taken by the JCS and the CSC to ensure that the SEC members have no conflict of interest for those proposals that they are asked to review. The SEC members will be required to formally declare that no conflict of interest exists at any time of their evaluation duty and will sign a confidentiality agreement concerning all documents and the entire process.

Each pre-proposal will be allocated to at least two (2) SEC members (one of whom will act as rapporteur). The SEC will meet, discuss the pre-proposals and establish a ranking list in accordance with the pre-proposals respective merit. Then, the CSC will decide, based on the SEC recommendations and budget consideration, how many pre-proposals will be invited to submit a full proposal. The JCS will communicate to each project coordinator the final decision with respect to their own application. Successful applicants will be invited by the JCS to submit a full proposal, with possible recommendations on the project from the SEC and the CSC.

5.4 Eligibility check of full proposals and second step of evaluation

An eligibility check of the full proposals will be performed by the JCS to ensure that they meet the formal criteria of the call and have not changed substantially from the respective pre-proposals. A full proposal may be excluded from further review, if criteria are not met or if the proposal objectives or the composition of the consortium deviate substantially from the previously submitted pre-proposal. In any case, major changes must be communicated in advance to the JCS, which will contact the concerned national/regional funding organizations to discuss the issue; a formal decision on whether such an exceptional change may be justified will be taken by the CSC. Each full proposal will be allocated to two (2) SEC members, possibly those who had
reviewed the corresponding pre-proposal, an additional methodology review by two (2) SEC
methodologist members, and to at least one (1) external reviewer. One of the SEC members will
be appointed as rapporteur. The SEC members and the external reviewers will independently
assess the full proposals according to the evaluation criteria mentioned above, and will deliver	heir evaluation reports to the JCS (via an electronic evaluation system).

5.4.1 Rebuttal stage
Once the evaluation by both the SEC members and the external reviewers is completed, each
proposal coordinator will have access, through the electronic submission system, to the
anonymous evaluation reports (not to the assigned scores) by the SEC members and the
external reviewers. At this stage, each coordinator will have the opportunity to comment the
evaluations, to reply to reviewer’s questions and to clarify factual errors or misunderstandings.
However, issues which are not related with reviewers’ comments or questions cannot be
addressed and the work plan cannot be modified. The resubmission of the full proposal is not
permitted in any case.

This response to reviewers’ comments is optional and must be submitted exclusively by the
coordinator of the proposal through the electronic submission system, which will be available from
the 7th of August 2018 to the 17th of August 2018 at 16:00 (Central European Summer Time,
CEST).

In preparation of the second SEC meeting, all SEC members will get access to the evaluation
reports and to the optional responses submitted by the coordinators following the rebuttal stage.
During the second SEC meeting, each full proposal will be presented by the rapporteur and
discussed by the SEC members on the basis of the individual evaluation reports to reach
consensus scoring. As a result of these discussions and as an outcome of the SEC meeting, a
ranking list of the full proposals will be established. In addition, each rapporteur will draw up an
evaluation summary report resulting from the debate at the SEC meeting, which will be
anonymized and sent by the JSC to the proposal Coordinator.

5.5 Funding decision
After the end of the evaluation process, on the basis on the ranking list established by the SEC
and on the resources available for committed funds, the CSC will establish a final list of the
projects to be funded. The CSC recommendations will be sent to the national/regional funding
organisations for their final decisions.
The JCS will communicate to all project coordinators the final decision along with the summary of
the evaluation conclusions (evaluation summary report), prepared by each rapporteur.
6. FINANCIAL AND LEGAL ISSUES

6.1 Funding model and funding details
The TRANSCAN-2 JTC 2017 funding organisations have agreed to launch a joint call using the “virtual common pot” funding model. This means that funding will be made available by each national/regional funding organisation according to their specific regulations, for research groups in their country/region.

The funding rate within the call will be variable up to a maximum of 100% of the funds requested, according to national/regional rules. Funding is granted for a maximum of three years according to national regulations. Each research project partner (including the project coordinator) will get a separate funding contract/letter of grant according to national/regional regulations from his/her national/regional funding institutions.

As a general rule, no changes to the composition of research consortia or in budget may occur during the contract/letter of grant. Any minor changes will have to be well justified and the relevant funding organizations will decide upon the proper action to be taken. However, in case of major changes, an independent expert may be consulted to help with the final decision of the funding organizations. The research partners shall inform the coordinator, the JCS and her/his national contact person of any event that might affect the implementation of the project.

Depending on the time needed for the administration of granting funds to the respective national/regional research groups, individual tasks of a research consortium are expected to start by April 2019. The official start date shall be communicated in the annual reports and shall appear in the consortium agreement established in accordance to section 6.2 below.

6.2 Research Consortium Agreement, ownership of intellectual property rights, ethical issues
It is mandatory for a funded research project consortium to sign a Consortium Agreement (CA), addressing the issues indicated in the document "Guidelines for Applicants". See link for an EU example of a CA. For the composition of the CA, the research consortium is strongly recommended to see legal assistance of a TTO (Technology Transfer Office) at their own institute. Also, the research consortium is strongly recommended to sign this CA before the official project start date. In any case the CA has to be signed no later than six months after the official project start date. The signed consortium agreement must be made available to the concerned TRANSCAN-2 JTC 2017 funding organizations.

Results and foreground IPR resulting from projects funded through the TRANSCAN-2 JTC 2017 will be owned by the organization that employs the participant who creates the results, respecting to international/national/regional rules on IPR. If several participants have jointly carried out work generating new IPR, they shall agree amongst themselves in the CA as to the allocation of ownership of IPR, taking into account their contributions to the creation of those IPR. European
Commission’s guidelines on IPR issues should be respected in TRANSCAN-2 JTC 2017 research projects.

The owner may protect foreground IPR at its own cost and risk, and grants the other parties in the research consortium free user rights of both background and foreground IPR as far as necessary for executing the TRANSCAN-2 JTC 2017 research project. Licencing or transfer of foreground IPR between consortium partners or to third parties will be on the basis of a market-based compensation. The consortium partners grant each other a free user right of foreground IPR for non-commercial research and education purposes during and after the TRANSCAN-2 JTC 2017 research project.

The results of the research project and IPR created should be disseminated and made available for use, whether for commercial purposes or not, in order to maximize public benefit. Dissemination should not conflict protection of IPR. In the CA the parties agree on the procedures for delaying dissemination of results to enable protection of IPR. The delay may not exceed 120 days after the originally planned date of dissemination.

The TRANSCAN-2 JTC 2017 funding organizations shall have the right to use reports, documents, and information submitted by the research partners for their own purposes, provided that the owners’ rights are respected.

Any ethical issues, arising for instance if a research project includes a study on patients, should be addressed at the proposal submission stage, and subsequent authorization presented at the latest to the national/regional funding organizations, before the process of grant negotiation.

6.3 Confidentiality of proposals

Proposals and any relating information shall be kept confidential by the SEC members (including SEC methodologist members), the external reviewers and the CSC members. Proposals shall not be used for any purpose other than the evaluation and subsequent monitoring of the funded projects.

Full proposals will be required to include a publishable summary, which will clearly identify the main goals of the project. If a proposal is funded, this information will be published on the TRANSCAN-2 website. All other project details shall remain strictly confidential.

7. REPORTING AND DISSEMINATION

The coordinator of a funded transnational research consortium must submit annual scientific project reports (within 4 months after the end of a calendar year), and a final scientific project report (within 3 months after the end of the project) to TRANSCAN-2. All reports must be written in English and comply with the reporting form templates (one for the annual reports and one for the final report) that will be provided to the coordinators of the funded projects in due time.

In addition to these centrally-administered TRANSCAN-2 reports, principal investigators may be
asked to submit financial and/or scientific reports to their national/regional funding organizations. Each individual contract/letter of grant will be monitored by the respective national/regional funding organizations. 

In case of serious difficulties in the conduct of the research project, the coordinator shall promptly inform the JCS and the relevant funding organizations. These funding organizations will decide upon the proper actions to be taken.

Funding recipients must ensure that all results (publications, etc.) arising from the project include a proper acknowledgement that the project is collectively supported by the national funding organisations under the framework of the ERA-NET TRANSCAN-2 initiative. The coordinators and/or principal investigators may be invited to present the results of their projects at TRANSCAN-2 symposia.

8. CONTACT AND FURTHER INFORMATION

The JCS is set up at the Alliance Against Cancer, Italy. The JCS will assist the CSC during the implementation of JTC 2017 as well as during the monitoring phase (until 3 months after the funded research projects have ended). The JCS will be responsible for the central management of the call evaluation and monitoring. The JCS will be the primary contact referring to the TRANSCAN-2 JTC 2017 procedures between the research consortia, the funding organizations (CSC) and the peer reviewers (SEC members and external experts).

Further information on TRANSCAN-2, the TRANSCAN-2 JTC 2017 and its planned time schedule is available at the TRANSCAN website: http://www.transcanfp7.eu. Before submitting a proposal, it is strongly advised to contact the national/regional funding organizations for any questions regarding JTC 2017 (see Annex 1).
<table>
<thead>
<tr>
<th>Country / region</th>
<th>Funding organisation</th>
<th>Website</th>
<th>National / regional contact</th>
</tr>
</thead>
</table>
| Austria          | Austrian Science Fund (FWF) | [http://www.fwf.ac.at/](http://www.fwf.ac.at/) | **Dr. Stephanie RESCH**  
Tel: +43-1-505 67 40-8201  
E-mail: stephanie.resch@fwf.ac.at  

**Anita STÜRTZ**  
Phone: +43(1) 505 67 40-8206  
Email: anita.stuertz@fwf.ac.at |
| Belgium: Flanders | Research Foundation - Flanders (FWO) | [www.fwo.be](http://www.fwo.be) | **Dr. Alain Deleener**  
Science Policy Advisor Strategic Research Programmes  
Tel. +32 2 550 15 95  

**Toon MONBALIU**  
Advisor Research Affairs  
Tel. +32 2 550 15 70  
Egmonstraat 5  
1000 Brussels  
Belgium  
E-mail: eranet@fwo.be |
| Belgium: French speaking region | Fund for Scientific Research (F.R.S.-FNRS) | [www.frs-fnrs.be](http://www.frs-fnrs.be) | **Mr. Joël Groeneveld**  
Policy Officer  
FRS-FNRS  
Rue d’Egmont 5 -1000 Brussels  
Belgium  
Tel. +32 2 504 92 70  
E-mail: joel.groeneveld@frs-fnrs.be |
| Estonia          | Estonian Research Council (ETAg) | [www.etag.ee](http://www.etag.ee) | **Mr Argo SOON**  
Estonian Research Council  
Soola 8  
51013 Tartu  
Estonia  
Tel: +372 7300 372  
E-mail: argo.soon@etag.ee |
<table>
<thead>
<tr>
<th>Country</th>
<th>Organization</th>
<th>Website</th>
<th>Contact Person</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>National Cancer Institute (INCa)</td>
<td><a href="http://www.e-cancer.fr">www.e-cancer.fr</a></td>
<td>Charlotte GUDEWICZ, Research and Innovation Division</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>52 avenue André Morizet 92513 Boulogne Billancourt Cedex, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tel: +33 (0)1 41 10 15 14 E-mail: <a href="mailto:cgudewicz@institutcancer.fr">cgudewicz@institutcancer.fr</a></td>
</tr>
<tr>
<td></td>
<td>ARC French Foundation for Cancer Research (ARC Foundation)</td>
<td><a href="http://www.fondation-arc.org">www.fondation-arc.org</a></td>
<td>Juliane HALFTERMEYER, Translational Research &amp; Innovation - Fondation ARC pour la recherche sur le cancer 9, Rue Guy Moquet – BP 90003 Villejuif Cedex, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tel: +33 (0)1 45 59 59 51 E-mail: <a href="mailto:JHalftermeyer@fondation-arc.org">JHalftermeyer@fondation-arc.org</a></td>
</tr>
<tr>
<td>Germany</td>
<td>Federal Ministry of Education and Research (BMBF) / PT-DLR</td>
<td><a href="http://www.gesundheitsforschung-bmbf.de">www.gesundheitsforschung-bmbf.de</a></td>
<td>Akin Akkoyun, Project Management Agency of the German Aerospace Center (PT-DLR) - Health Research-Heinrich-Konen-Str. 1 D-53227 Bonn, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tel: +49 (0)228/3821-1864 Fax: +49 (0)228/3821-1257 E-mail: <a href="mailto:akin.akkoyun@dlr.de">akin.akkoyun@dlr.de</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hubert Misslisch, Project Management Agency of the German Aerospace Center (PT-DLR) - Health Research-Heinrich-Konen-Str. 1 D-53227 Bonn, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tel: +49 (0)228/3821-1271 Fax: +49 (0)228/3821-1257 E-mail: <a href="mailto:hubert.misslisch@dlr.de">hubert.misslisch@dlr.de</a></td>
</tr>
<tr>
<td>Greece</td>
<td>General Secretariat for Research and Technology, Ministry of Education, Research and Religious Affairs (GSRT)</td>
<td><a href="http://www.gsrt.gr">www.gsrt.gr</a></td>
<td>Sofia DIMITROPOULOU, General Secretariat for Research &amp; Technology International S&amp;T Cooperation Directorate Division of Bilateral &amp; Multilateral Relations 14-18, Mesogeion Av., 11510 Athens, Greece</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tel.: (+30) 210 7458187 Fax: (+30) 210 7714153 E-mail: <a href="mailto:s.dimitropoulou@gsrt.gr">s.dimitropoulou@gsrt.gr</a></td>
</tr>
<tr>
<td>Country</td>
<td>Organisation/Contact Information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td><strong>The Chief Scientist Office in the Ministry of Health (CSO-MOH)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="http://www.health.gov.il">www.health.gov.il</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Ayelet ZAMIR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TRANSCAN-2 National Coordinator</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chief Scientist Office</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ministry of Health Israel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tel: +972-2-508-2168</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>E-mail: <a href="mailto:ayelet.zamir@moh.gov.il">ayelet.zamir@moh.gov.il</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td><strong>Ministry of Health (MoH)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="http://www.salute.gov.it">www.salute.gov.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Gaetano GUGLIELMI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directorate General for Health Research and Innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ministry of Health – Ministero della Salute</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Viale Giorgio Ribotta, 5 00144 Rome, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phone: +39 065994.3528</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>E-mail: <a href="mailto:g.guglielmi@sanita.it">g.guglielmi@sanita.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Silvia PARADISI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directorate General for Health Research and Innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ministry of Health – Ministero della Salute</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phone: +39 064990 6553</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>E-mail: <a href="mailto:silvia.paradisi@iss.it">silvia.paradisi@iss.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td><strong>Alliance Against Cancer (ACC)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="http://www.alleanzacontroilcancro.it">www.alleanzacontroilcancro.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Gennaro CILIBERTO</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alliance Against Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Via Giorgio Ribotta 5, 00144 Rome, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tel: +39 065994.3412</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:gennaro.ciliberto@ifo.gov.it">gennaro.ciliberto@ifo.gov.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Maddalena BARBA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alliance Against Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Via Giorgio Ribotta 5, 00144 Rome, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tel: +39 065994.3412</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:maddalena.barba@gmail.com">maddalena.barba@gmail.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td><strong>Lombardy Foundation for Biomedical Research (FRRB)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="http://www.frrb.it">www.frrb.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mrs. Carmen De Francesco</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Via Taramelli 12, 20124 - Milano</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tel: +39 02 67650170</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:carmen.defrancesco@frrb.it">carmen.defrancesco@frrb.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Paola Larghi, PhD</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Via Taramelli 12, 20124 - Milano</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tel: +39 02 67650173</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:paola.larghi@frrb.it">paola.larghi@frrb.it</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Organization</td>
<td>Website</td>
<td>Contact Details</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------</td>
<td>-------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Latvia       | State Education Development Agency (VIAA)         | www.viaa.gov.lv                      | Dr. Maija Bundule  
State Education Development Agency (VIAA)  
Valnu str. 1, LV-1050 Riga  
Tel: +371 – 67785423  
E-Mail: Maija.Bundule@viaa.gov |
|              |                                                   |                                     | Dr. Uldis Berkis  
State Education Development Agency (VIAA)  
Valnu str. 1, LV-1050 Riga  
Tel: +371 – 29472349  
E-Mail: Uldis.Berkis@viaa.gov.lv |
| Luxembourg   | National Research Fund                             | www.fnr.lu                           | Frank Glod, PhD  
Head of Unit - Strategic Research Programmes  
Maison du Savoir  
2, avenue de l'Université  
L-4365 Esch-sur-Alzette  
Postal Address : B.P. 1777 I L-1017 Luxembourg  
Tel: +352 261925-33  
frank.glod@fnr.lu |
| The Netherlands | Dutch Cancer Society (DCS)                         | www.kwf.nl                           | Miranda WIJDENES  
KWF Kankerbestrijding  
Delflandlaan 17  
Postbus 75508 1070 AM Amsterdam  
The Netherlands  
Tel: + 31 20 5700500  
Email: mwijdenes@kwf.nl |
| Poland       | National Centre for Research and Development (NCBR) | www.ncbr.gov.pl                      | Dominika Mickiewicz  
Section for international programmes  
National Centre for Research and Development  
ul. Nowogrodzka 47a, 00-695 Warszawa, Poland  
+48 22 39 07 139  
dominika.mickiewicz@ncbr.gov.pl |
<table>
<thead>
<tr>
<th>Country</th>
<th>Organization</th>
<th>Website</th>
<th>Contact Person</th>
<th>Address</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portugal</td>
<td>Foundation for Science and Technology (FCT)</td>
<td><a href="http://www.fct.pt">www.fct.pt</a></td>
<td>Marta ABRANTES</td>
<td>Departamento das Relações Internacionais Fundação para a Ciência e Tecnologia (FCT) Av. D. Carlos I, nº126 - 7º 1249 - 074 Lisboa, Portugal Tel. +351 213911596 <a href="mailto:marta.abrantes@fct.pt">marta.abrantes@fct.pt</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rui DURÃO</td>
<td>Departamento das Relações Internacionais Fundação para a Ciência e Tecnologia (FCT) Av. D. Carlos I, 126 – 7ª 1249-074 Lisboa, Portugal Tel.: +351 213 911 532 <a href="mailto:rui.durao@fct.pt">rui.durao@fct.pt</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>Slovak Academy of Sciences (SAS)</td>
<td><a href="http://www.sav.sk">www.sav.sk</a></td>
<td>Mr. Jan BARANCIK, PhD</td>
<td>Department for International Cooperation of SAS, Slovak Academy of Sciences, Štefánikova 49 814 38 - Bratislava, Slovak Republic Tel: +421 2 5751 0137 E-mail: <a href="mailto:barancik@up.upsav.sk">barancik@up.upsav.sk</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mr. Martin NOVAK, PhD</td>
<td>Department for International Cooperation of SAS, Slovak Academy of Sciences, Štefánikova 49 814 38 - Bratislava, Slovak Republic Tel: +421 2 5751 0179 E-mail: <a href="mailto:mnovak@up.upsav.sk">mnovak@up.upsav.sk</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>National Institute of Health Carlos III (ISCIII)</td>
<td><a href="http://www.isciii.es">www.isciii.es</a></td>
<td>Dori CAMPO</td>
<td>Deputy Directorate of International Programmes for Research and Institutional Relations National Institute of Health Carlos III Email: <a href="mailto:doricampo@isciii.es">doricampo@isciii.es</a> Tel.: +34 91 822 2874</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Organization</td>
<td>Website</td>
<td>Contact Person</td>
<td>Details</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Spain     | The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT) | www.ficyt.es      | Inés Rey HIDALGO                   | Innovation Management Department  
E-mail: inesrey@ficyt.es  
Tel: +34 985 20 74 34 |
| Spain     | Spanish Association Against Cancer Scientific Foundation (FC AECC)            | www.aecc.es      | Dr. Marta PUYOL ESCOLAR           | Fundación científica de la AECC  
C/Amador de los ríos, 5  
28010-Madrid  
Tel: +34 91 3108207  
Email: marta.puyol@aecc.es |
| Taiwan    | Ministry of Science and Technology (MoST)                                     | www.most.gov.tw  | Dr. Louis CHEN                     | Ministry of Science and Technology (Taiwan) No. 106, Sec 2 Heping E. Road, Taipei, 106Taiwan, R.O.C  
Tel:+886-2-2737-7959  
E-mail: ymchen@most.gov.tw |
| Turkey    | The Scientific and Technological Research Council of Turkey (TÜBİTAK)         | www.tubitak.gov.tr | Ms. A. Özge GÖZAY                  | TÜBİTAK Tunus Caddesi No:80 06100  
Kavaklidere / Ankara, Turkey  
Tel: + 90 312 2981893  
E-mail: ncphealth@tubitak.gov.tr |
### ANNEX 2. INDICATIVE FUNDING COMMITMENT OF THE FUNDING ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2017

<table>
<thead>
<tr>
<th>Country/ Region</th>
<th>Participating funding organisation</th>
<th>Envisioned amount of funding (Mio € for 3 years)</th>
<th>Anticipated number of fundable research groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Austrian Science Fund</td>
<td>0,700</td>
<td>2</td>
</tr>
<tr>
<td>Belgium: Flanders</td>
<td>Research Foundation - Flanders (FWO)</td>
<td>0,200</td>
<td>1</td>
</tr>
<tr>
<td>Belgium: French speaking region</td>
<td>Fund for Scientific Research - FNRS (F.R.S.-FNRS)</td>
<td>0,200</td>
<td>1</td>
</tr>
<tr>
<td>Estonia</td>
<td>Estonian Research Council (ETAg)</td>
<td>0,300</td>
<td>2</td>
</tr>
<tr>
<td>France</td>
<td>National Cancer Institute (INCa)</td>
<td>1,500</td>
<td>5 – 10</td>
</tr>
<tr>
<td></td>
<td>ARC French Foundation for Cancer Research (ARC Foundation)</td>
<td>0,700</td>
<td>1 – 3</td>
</tr>
<tr>
<td>Germany</td>
<td>Federal Ministry of Education and Research (BMBF) / PT- DLR</td>
<td>3,000</td>
<td>10-12</td>
</tr>
<tr>
<td>Greece</td>
<td>General Secretariat for Research and Technology, Ministry of Education, Research and Religious Affairs (GSRT)</td>
<td>1,000</td>
<td>4-5</td>
</tr>
<tr>
<td>Israel</td>
<td>The Chief Scientist Office of the Ministry of Health (CSO-MOH)</td>
<td>0.300</td>
<td>2</td>
</tr>
<tr>
<td>Italy</td>
<td>Ministry of Health (MoH)</td>
<td>3,000</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Alliance Against Cancer (ACC)</td>
<td>0,300</td>
<td>1-2</td>
</tr>
<tr>
<td></td>
<td>Lombardy Foundation for Biomedical Research (FRRB)</td>
<td>1,250</td>
<td>2-3</td>
</tr>
<tr>
<td>Latvia</td>
<td>State Education Development Agency (VIAA)</td>
<td>0,420</td>
<td>2</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>National Research Fund Luxembourg (FNR)</td>
<td>0,300</td>
<td>1-2</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>Dutch Cancer Society (DCS)</td>
<td>1,000</td>
<td>2-3</td>
</tr>
<tr>
<td>Country</td>
<td>Organization</td>
<td>Funding</td>
<td>Funding Level</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------</td>
<td>---------------</td>
</tr>
<tr>
<td>Poland</td>
<td>National Centre for Research and Development (NCBR)</td>
<td>0.600</td>
<td>2-3</td>
</tr>
<tr>
<td>Portugal</td>
<td>Foundation for Science and Technology (FCT)</td>
<td>0.100</td>
<td>1</td>
</tr>
<tr>
<td>Slovakia</td>
<td>Slovak Academy of Sciences (SAS)</td>
<td>0.210</td>
<td>1-2</td>
</tr>
<tr>
<td>Spain</td>
<td>National Institute of Health Carlos III (ISCIII)</td>
<td>0.250</td>
<td>2-3</td>
</tr>
<tr>
<td></td>
<td>The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT)</td>
<td>0.200</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Scientific Foundation Spanish Association Against Cancer (SF AECC)</td>
<td>0.250</td>
<td>2-3</td>
</tr>
<tr>
<td>Taiwan</td>
<td>Ministry of Science and Technology (MoST)</td>
<td>0.500</td>
<td>2-3</td>
</tr>
<tr>
<td>Turkey</td>
<td>The Scientific and Technological Research Council of Turkey (TÜBİTAK)</td>
<td>0.300</td>
<td>2</td>
</tr>
</tbody>
</table>
# ANNEX 3. ELIGIBILITY OF BENEFICIARY INSTITUTIONS FOR THE FUNDING ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2017

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Participating funding organisation</th>
<th>Eligible beneficiary institution(1)</th>
<th>Academia</th>
<th>Clinical/ public health</th>
<th>Enterprise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Austrian Science Fund (FWF)</td>
<td>Yes (2)</td>
<td>Yes (2)</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td>Belgium: Flanders</td>
<td>Research Foundation - Flanders (FWO)</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Belgium: French speaking region</td>
<td>Fund for Scientific Research - FNRS (F.R.S.-FNRS)</td>
<td>Yes</td>
<td>No (except the ISP-Institut de Santé Publique)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>Estonian Research Council (ETAg)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (if requirements for research staff are fulfilled)</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>National Cancer Institute (INCa)</td>
<td></td>
<td></td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>ARC French Foundation for Cancer Research (ARC Foundation)</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>Federal Ministry of Education and Research (BMBF) / PT-DLR</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>General Secretariat for Research and Technology, Ministry of Education, Research and Religious Affairs (GSRT)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>The Chief Scientist Office of the Ministry of Health (CSO-MOH)</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Funding Body</td>
<td>EU Funding</td>
<td>Other Funding</td>
<td>National Funding</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------</td>
<td>------------</td>
<td>---------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>Ministry of Health (MoH)</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alliance Against Cancer (ACC)</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lombardy Foundation for Biomedical Research (FRRB)</td>
<td>Yes (in partnership with IRRCS or ASST)</td>
<td>Yes (ASST and public and Private IRCCS)</td>
<td>NO</td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>State Education Development Agency (VIAA)</td>
<td>Yes, must be listed in the Latvian Registry of Scientific institutions</td>
<td>Only if listed into the Latvian Registry of Scientific institutions</td>
<td>Must be listed in the Latvian Commercial Registry, have main research activity in Latvia</td>
<td></td>
</tr>
<tr>
<td>Luxembourg</td>
<td>National Research Fund Luxembourg (FNR)</td>
<td>Yes (under the conditions specified in the national rules)</td>
<td>Yes (under the conditions specified in the national rules)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>Dutch Cancer Society (DCS)</td>
<td>Yes, according to grant conditions KWF Kankerbestrijding</td>
<td>Yes, research institutes and university hospitals according to grant conditions KWF Kankerbestrijding</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>National Centre for Research and Development (NCBR)</td>
<td>Yes, according to the Principles of Financing Science (consolidated text: Journal of Laws of 2016 item 2045, as amended). Organization must be in Poland registered</td>
<td>Yes, according to the Principles of Financing Science (consolidated text: Journal of Laws of 2016 item 2045, as amended). Organization must be in Poland registered</td>
<td>Yes, according to the Principles of Financing Science (consolidated text: Journal of Laws of 2016 item 2045, as amended). Organization must be in Poland registered</td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>Foundation for Science and Technology (FCT)</td>
<td>Yes, according to the national rules</td>
<td>Yes, according to the national rules</td>
<td>Yes, according to the national rules (max. of 50% of the total budget)</td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>Slovak Academy of Sciences (SAS)</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Institution</td>
<td>Yes/No</td>
<td>Yes/No</td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>National Institute of Health Carlos III (ISCIII)</td>
<td>Yes</td>
<td>Only under the conditions specified in the national rules</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT)</td>
<td>Yes</td>
<td>according to the regional call grant conditions</td>
<td>Yes, according to the regional call grant conditions</td>
<td>Yes, according to the regional call grant conditions</td>
</tr>
<tr>
<td></td>
<td>Scientific Foundation Spanish Association Against Cancer (SF AECC)</td>
<td>Please refer annex 4</td>
<td>Please refer annex 4</td>
<td>Please refer annex 4</td>
<td></td>
</tr>
<tr>
<td>Taiwan</td>
<td>Ministry of Science and Technology (MoST)</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>The Scientific and Technological Research Council of Turkey (TÜBITAK)</td>
<td>Yes (under the conditions specified in the national rules)</td>
<td>Yes (under the conditions specified in the national rules)</td>
<td>Yes (only research SMEs under the conditions specified in the national rules)</td>
<td></td>
</tr>
</tbody>
</table>

Please note that the information on this table is only indicative. Applicants are encouraged to contact their national/regional contact points for further information. (1) The eligibility of companies and institutions is subject to different regulations in the participating country/region. Further details regarding the eligible beneficiaries and other national eligibility criteria and requirements are available on the “Guidelines for Applicants” and the TRANSCAN website (http://www.transcanfp7.eu/).

(2) Applications for projects from FWF (Austria) may only be submitted by single natural persons. Affirmation of the research institution (academia, clinical/public health, enterprise) of the applicant is mandatory.
## ANNEX 4. NATIONAL/REGIONAL REGULATIONS AND CONTACT INFORMATION

<table>
<thead>
<tr>
<th>Country</th>
<th>Austria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>Austrian Science Fund (FWF)</td>
</tr>
</tbody>
</table>
| National contact persons | Stephanie Resch Phone: +43 (1) 505 67 40-8201, E-mail: stephanie.resch@fwf.ac.at  
Anita Stürtz Phone: +43 (1) 505 67 40-8206, E-mail: anita.stuertz@fwf.ac.at |
| Funding commitment | 0,7 M € |
| Anticipated number of fundable project partners | 2 |
| Maximum funding per grant awarded to a project partner | 0,4 M € |
| Eligibility of projects | Refer to call text |
| Eligibility of a partner as a beneficiary institution | Individual researcher or teams of researchers, working in any kind of non-profit organisation: e.g. University, University hospital, Non-university research institute |
| Eligibility of principal investigator or other research team member | Individual researcher or teams of researchers, working in any kind of non-profit organisation: e.g. University, University hospital, Non-university research institute  
**Please note** that started on April 1, 2016, the number of ongoing/approved/submitted projects in which one researcher can serve as PI will be limited to two in the Stand-Alone Projects Programme, International Programmes (including ERA-Net projects!), Clinical Research and Arts-Based Research Programmes. PIs that already have two ongoing/approved/submitted projects will not be permitted to submit another application within those programmes until 12 months before the end of one of their ongoing projects. You are strongly advised to contact the national representative in case you may be affected by this regulation. |
| Eligibility of costs, types and their caps | Only project-specific costs (see rules for FWF stand-alone project) Personnel, Consumables, Animals, Subcontracts, Equipment, Travel, Documentation (Note: publication costs are handled according to FWF stand-alone projects) Overhead is not an eligible cost.  
Please refer also to the general FWF Funding Guidelines:  
http://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/ |
<p>| Submission of the proposal at the national level | Submission of the pre-proposal as well full-proposal at the national/regional level is necessary. Detailed information may be found under <a href="http://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/">http://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/</a> |
| Further guidance | <a href="http://www.fwf.ac.at">http://www.fwf.ac.at</a> |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>Belgium (Flanders)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>Research Foundation Flanders (FWO)</td>
</tr>
</tbody>
</table>
| National contact persons | dr. Alain Deleener  
Science Policy Advisor Strategic Research Programmes  
Tel. +32 2 550 15 45  
Toon Monbaliu  
Advisor Research Affairs  
Tel. +32 2 550 15 70  
E-mail: eranet@fwo.be |
| Funding commitment | 0,2 M €                                                                 |
| Anticipated number of fundable project partners | 1                                                                 |
| Maximum funding per grant awarded to a project partner | 0,2 M €                                                                 |
| Eligibility of projects | Refer to call text.                                                            |
| Eligibility of a partner as a beneficiary institution | Art. 9 of the FWO-regulations on the regular research projects is applicable. In this article is stated who can apply as a supervisor or co-supervisor for a research project:  
| Eligibility of principal investigator or other research team member | Art. 9 of the FWO-regulations on the regular research projects is applicable. In this article is stated who can apply as a supervisor or co-supervisor for a research project:  
| Eligibility of costs, types and their caps | Funding money can be used for staff, consumables and infrastructure. The minimal and maximal amounts of money allowed per cost category, as applicable for the regular FWO-projects, are not applicable for the projects funded by FWO in ERA-NET.  
Overhead is not an eligible cost. Notwithstanding, FWO pays the host institutions of a project 6% overhead on top of the funding amount. |
<p>| Submission of the proposal at the national level | Submission of the proposal at the national/regional level is NOT necessary. |
| Further guidance | It is strongly advised to contact FWO before submission, this in order to verify the researchers’ eligibility. |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>Belgium (French speaking community)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>Fund for Scientific Research – FNRS (F.R.S.-FNRS)</td>
</tr>
</tbody>
</table>
| National contact persons | Mr. Joël Groeneveld  
Policy Officer  
Tel. +32 2 504 92 70  
joel.groeneveld@frs-fnrs.be |
<p>| Funding commitment | 0,2 M € |
| Anticipated number of fundable project partners | 1 |
| Maximum funding per grant awarded to a project partner | 0,2 M € |
| Eligibility of projects | All eligibility rules and criteria can be found in the PINT-MULTI regulations |
| Eligibility of a partner as a beneficiary institution | |
| Eligibility of principal investigator or other research team member | |
| Eligibility of costs, types and their caps | |
| Submission of the proposal at the national level | YES. Applicants must provide basic administrative data by submitting an administrative application on Semaphore for the same deadline as the consortium application is submitted. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS. |
| Further guidance | It is strongly advised to contact FNRS before submission, this in order to verify the researchers’ eligibility. |</p>
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th>Estonia</th>
</tr>
</thead>
</table>
| **Funding organisation** | Estonian Research Council (ETAg)  
www.etag.ee |
| **National contact persons** |  
Mr Argo SOON  
Estonian Research Council  
Soola 8, 51013 Tartu  
Estonia  
Tel: +372 7300 372  
E-mail: argo.soon@etag.ee  
Mr Aare IGNAT  
Estonian Research Council  
Tel: +372 731 7364  
E-mail: aare.ignat@etag.ee |
| **National programme** | Mobilitas Pluss |
| **Funding commitment** | 0.300 Mio. € |
| **Anticipated number of fundable project partners** | 2 |
| **Maximum funding per grant awarded to a project partner** | 150 000 € |
| **Eligibility of projects** | According to call text |
| **Eligibility of a partner as a beneficiary institution** | Legal bodies such as universities, research institutions, enterprises, NGOs and other, provided availability of research staff that meets eligibility criteria described below. |
| **Eligibility of principal investigator or other research team member** | The Principal Investigator is the researcher who is appointed to be responsible for the use of the grant for its specific purpose and for the productive realisation of the project. The principal investigator:  
- Must possess either the Estonian nationality or citizenship or be a permanent resident of Estonia.  
- Has an updated profile in the Estonian Research Information System (ETIS).  
- Has as a rule entered into an employment relationship with the Host Institution, which is the basis of the realisation of the grant project and through which the grant shall be allocated to the Principal Investigator.  
- Must be a holder of the doctoral degree of Estonia or an equivalent academic degree (both awarded by the deadline of submission of the grant application, at the latest).  
- Must have published within the last five years prior to the proposal’s submission deadline at least three publications, which comply with the requirements of clauses 1.1 of the classification of publications of the ETIS, or at least five publications, which comply with the requirements of clauses 1.1, 1.2, 2.1 and 3.1 of the classification of publications of the ETIS; international patents are equalised with publications of clause 1.1.; the monographs are equalised to each author with three publications mentioned in clause 1.1 if the number of its authors is three or less. If the applicant has been on the parental leave or in the compulsory military service within these last five years, the deadline of the publication requirement shall be extended by the time stayed on the parental leave or compulsory military service. |
| **Eligibility of costs, types and their caps** | 1. A budget of proposal shall consist of the research expenses and the overhead costs, through which the grant project is to be carried out.  
2. The research expenses consist of personnel costs, travel costs, other direct costs and subcontracting |
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>JTC 2017</td>
<td>CALL TEXT</td>
</tr>
<tr>
<td>costs. The expenses on research are clearly required to carry out the project and respectively identifiable. All eligible costs are set in the decree of Mobilitas Pluss.</td>
<td></td>
</tr>
<tr>
<td>3. Double funding of activities already having contributions is not acceptable. If the project or parts of the project are already being funded from other sources or the Host Institution is currently applying for other funding for the same project, the Host Institution is required to provide this information.</td>
<td></td>
</tr>
<tr>
<td>4. Only costs which have been made between the signature of the grant agreement and 31.12.2022 are eligible.</td>
<td></td>
</tr>
<tr>
<td>5. Remuneration may only be paid out of the grant to the Principal Investigator and main participants in the project according to the time they participate in the grant project and their total salary cost.</td>
<td></td>
</tr>
<tr>
<td>6. Travel costs cover expenses for transport, accommodation and daily allowances (except in case of internal travel).</td>
<td></td>
</tr>
<tr>
<td>7. Subcontracting costs cover generally only additional or complementary tasks (e.g. costs for translation, analyses, etc.) to the third parties. Core project research tasks should not be subcontracted. Subcontracting costs may not exceed 10% of the total costs.</td>
<td></td>
</tr>
<tr>
<td>8. Other direct costs are:</td>
<td></td>
</tr>
<tr>
<td>8.1. Consumables related to the project;</td>
<td></td>
</tr>
<tr>
<td>8.2. Costs for publishing and dissemination of project results (fair distribution of costs between partner should be followed);</td>
<td></td>
</tr>
<tr>
<td>8.3. Costs for organising the meetings/seminars/conferences (only in Estonia);</td>
<td></td>
</tr>
<tr>
<td>8.4. Fees for participating in scientific forums and conferences;</td>
<td></td>
</tr>
<tr>
<td>8.5. All other costs which are clearly required for the implementation of the project, are respectively identifiable and which comply with the eligible costs of the Mobilitas Pluss decree.</td>
<td></td>
</tr>
<tr>
<td>9. Overhead costs of the project are 15% of eligible direct personnel costs and should cover general expenses of the Host Institution and the Council. Two thirds (2/3) of the overhead will go to the Host Institution and one third (1/3) will be kept by the Council (for checking the compliance of the costs with the rules of the European Structural Funds).</td>
<td></td>
</tr>
<tr>
<td>10. Costs for equipment and services intended for public use (copying machine or printer publicly used, phone bills, copying service, etc.) shall be covered from the overhead fee.</td>
<td></td>
</tr>
<tr>
<td>11. Participants' personal expenses or expenses not directly related to the project are not eligible.</td>
<td></td>
</tr>
<tr>
<td>National phase</td>
<td>Not required. Only the submission of the joint proposal is required.</td>
</tr>
<tr>
<td>Further guidance</td>
<td>Estonian Research Council funds basic and applied research in terms of Organisation of Research and Development Act. Proposals may be submitted by the Estonia based research and development institutions in terms of Organisation of Research and Development Act.</td>
</tr>
<tr>
<td>Country</td>
<td>France</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td><strong>Funding organisations</strong></td>
<td>National Cancer Institute (INCa)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National contact persons</th>
<th>For INCa:</th>
<th>For ARC Foundation:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Charlotte GUDEWICZ, Research and Innovation Division 52 avenue André Morizet 92513 Boulogne Billancourt Cedex Email: <a href="mailto:cgudewicz@institutcancer.fr">cgudewicz@institutcancer.fr</a> Phone: + 33 (0)1 41 10 15 14</td>
<td>Juliane HALFTERMEYER Translational Research &amp; Innovation Fondation ARC pour la recherche sur le cancer 9 Rue Guy Môquet – BP 90003 94803 Villejuif Cedex, France Tel : +33 (0)1 45 59 59 51 E-mail: <a href="mailto:JHalftermeyer@fondation-arc.org">JHalftermeyer@fondation-arc.org</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National programme</th>
<th>French National Cancer Plan 2014-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding commitment</td>
<td>INCa: 1.5M euro ARC Foundation: 0.7M euro</td>
</tr>
<tr>
<td>Anticipated number of fundable project partners</td>
<td>INCa : From 5 to 10 research teams ARC Foundation: From 1 to 3 research teams</td>
</tr>
<tr>
<td>Maximum funding per grant awarded to a project partner</td>
<td>INCa and ARC Foundation do not have a maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget. However it is highly recommended to respect the available budget and anticipated number of fundable research groups mentioned above.</td>
</tr>
<tr>
<td>Eligibility of projects</td>
<td>Please refer to the call text</td>
</tr>
<tr>
<td>Eligibility of a partner as a beneficiary institution</td>
<td>- Public research institutions (university, EPST, EPIC, etc.) - Non-profit organisations (associations, foundations, etc.) - Hospitals or other health care providers (CHU, CRLCC, etc.)</td>
</tr>
<tr>
<td>Eligibility of principal investigator or other research team member</td>
<td>Reminder: Each transnational consortium must nominate a coordinator from one of the JTC 2016 countries/region. The coordinator will be responsible for the internal scientific management and for the external representation towards the JCS and the CSC. Each consortium partner will be represented by one principal investigator, who will be the contact person for the respective national/regional funding organization. - Public research institutions (university, EPST, EPIC, etc.)</td>
</tr>
</tbody>
</table>
Please note that for the reason that a personal investment is necessary for the good progress of the project, the PI is not allowed to coordinate simultaneously more than 3 projects funded by INCa.

<table>
<thead>
<tr>
<th>Eligibility of costs, types and their caps</th>
<th>For the research project:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Equipment: up to 150 000 € including taxes per equipment; the total amount of the “equipment” expenses could not exceed a maximum of 30% of the total grant awarded</td>
</tr>
<tr>
<td></td>
<td>- Consumables and subcontracting</td>
</tr>
<tr>
<td></td>
<td>- Personnel costs</td>
</tr>
<tr>
<td></td>
<td>• Salary costs for permanent staff may be included in the budget with the exception of civil servants</td>
</tr>
<tr>
<td></td>
<td>• Please note that salary for PhD student is not eligible outside activities for capacity building.</td>
</tr>
<tr>
<td></td>
<td>- Travel and accommodation: only for the partner team members and for project management meetings; the total amount of the “Travel and accommodation” expenses could not exceed a maximum of 8% of the total grant awarded (Travel and accommodation costs to attend the intermediate and/or final TRANSCAN status symposium as specified in the Call text could be included in addition to the 8%)</td>
</tr>
<tr>
<td></td>
<td>- Indirect costs/overheads: not eligible</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>For the capacity building activities (Important reminder: These additional expenses should be asked to specifically reach the objectives mentioned in the dedicated section of the application forms):</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Part of salary costs for support staff (technician, engineer, etc)</td>
<td></td>
</tr>
<tr>
<td>- Part of salary for scientist, physician, veterinarian or pharmacist (short term training, PhD student, post-doctoral fellowship)</td>
<td></td>
</tr>
<tr>
<td>- Travel and accommodation for exchanges programme</td>
<td></td>
</tr>
<tr>
<td>Costs for project management workshops and dissemination events such as symposium are not eligible in this section.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National phase</th>
<th>Not required. Only the submission of the joint proposal is required.</th>
</tr>
</thead>
</table>

<p>| Further guidance | Not applicable |</p>
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th>Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding organisations</strong></td>
<td>Federal Ministry of Education and Research (BMBF)</td>
</tr>
</tbody>
</table>
| **National contact persons** | **Dr. Akin Akkoyun**  
German Aerospace Center  
Project Management Agency | Health Research  
Heinrich-Konen-Str. 5  
53227 Bonn  
Email: akin.akkoyun@dlr.de  
Phone: + 49 (0) 228 3821 1864 |
| **National programme** | German Health Research Programme |
| **Funding commitment** | 3.0 Mio Euro |
| **Anticipated number of fundable project partners** | From 10 to 12 research teams |
| **Maximum funding per grant awarded to a project partner** | BMBF does not have a maximum funding per grant; the requested budget depends on the scientific needs and must be duly justified. However, it is highly recommended to respect the available budget and anticipated number of fundable research groups mentioned above. |
| **Eligibility of projects** | Please refer to the call text |
| **Eligibility of a partner as a beneficiary institution** | - Public research institutions  
- Non-profit organisations (associations, foundations, etc.)  
- Hospitals or other health care providers  
- Enterprises |
| **Eligibility of costs, types and their caps** | - Personnel costs  
- Consumables and subcontracting  
- Equipment  
- Travel and accommodation |
<p>| <strong>National phase</strong> | Not required. Only the submission of the joint proposal is required. |
| <strong>Further guidance</strong> | Not applicable |</p>
<table>
<thead>
<tr>
<th>Country / Region</th>
<th>Greece</th>
</tr>
</thead>
</table>
| Funding organisation | General Secretariat for Research and Technology (GSRT)  
  www.gsrt.gr |
| National Programme | National Research and Innovation Strategy for Smart Specialization 2014-2020  
| National contact person | DIMITROPOULOU Sofia  
  s.dimitropoulou@gsrt.gr  
  Tel.: 00302107458187 |
| Funding commitment | 1.0 ME |
| Maximum funding per grant awarded to a project partner | Up to 0,2- 0,25 ME per consortium |
| Anticipated number of fundable research partners | 4-5 projects tentatively envisaged to be funded |
| Eligibility of project duration | 36 months. A possible extension of the duration under conditions can be accepted maximum up to the1/3 of the initial duration taking in account the starting date without modifying the scientific or increasing the financial part of the project. |
| Eligibility of a partner as a beneficiary institution | A. All legal entities (public and private sector) B. Individual enterprises |

### Aid for research and development projects (COMMISSION REGULATION (EU) No 651/2014 article 25)

#### 1. Kind of Research.

The aided part of the research and development project shall completely fall within one or more of the following categories:

(a) industrial research;

(b) experimental development;

#### 2. The eligible costs of research and development projects shall be allocated to a specific category of research and development and shall be the following:

(a) personnel costs: researchers, technicians and other supporting staff to the extent employed on the project; (regarding the individual enterprises the contracts should abide by the national legislation and guidelines)
(b) costs of instruments and equipment to the extent and for the period used for the project. Where such instruments and equipment are not used for their full life for the project, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible.

(c) Costs for of buildings and land, to the extent and for the duration period used for the project. With regard to buildings, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible. For land, costs of commercial transfer or actually incurred capital costs are eligible.

(d) costs of contractual research, knowledge and patents bought or licensed from outside sources at arm’s length conditions, as well as costs of consultancy and equivalent services used exclusively for the project;

(e) additional overheads and other operating expenses, including costs of materials, supplies and similar products, incurred directly as a result of the project;

3. The aid intensity for each beneficiary:

A. Public Research Institutes and Universities

The aid intensity can reach 100% for performing non economical activities in accordance to the point 19 of the article 2.1.1 of the «Framework for State aid for research and development and innovation» (2014/C 198/01)).

B. Private Sector

(a) 50 % of the eligible costs for industrial research;

(b) 25 % of the eligible costs for experimental development;

The aid intensities for industrial research and experimental development may be increased up to a maximum aid intensity of 80 % of the eligible costs as follows:

(a) by 10 percentage points for medium-sized enterprises and by 20 percentage points for small enterprises;

(b) by 15 percentage points if one of the following conditions is fulfilled:

(i) the project involves effective collaboration:

— between undertakings among which at least one is an SME, or is carried out in at least two Member States, or in a Member State and in a Contracting Party of the EEA Agreement, and no single undertaking
bears more than 70% of the eligible costs, or — between an undertaking and one or more research and knowledge-dissemination organisations, where the latter bear at least 10% of the eligible costs and have the right to publish their own research results;

(ii) the results of the project are widely disseminated through conferences, publication, open access repositories, or free or open source software.

Further information regarding the categorization of aid intensity and the eligibility of costs is available at the national guide published at GSRT website.

For more information please contact the NCP.

1. **Eligible costs as Indirect Costs**
   
   Up to 15% calculated on the basis of the personnel budget of the partner. Indirect costs are eligible for all Legal Entities.

2. **Upper funding limits for the eligible costs**
   
   Upper limit of the total public funding will be 200,000 € per project (including indirect costs). Please note that this amount can be increased to 250,000 € per project if Greek partner assumes the project coordination.

   The maximum state aid intensity will be calculated according to the provisions of the European state aid rules and regulations in force (type of research activity, size of the participating enterprise, collaborative research).

<table>
<thead>
<tr>
<th><strong>Submission of the proposal at the national level</strong></th>
<th>After the selection of the projects at European level a national call will be launched for the submission of the approved proposals at national level in order to be funded by GSRT.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Further guidance</strong></td>
<td>For more information you are strongly advised to contact the indicated NCP for the current call</td>
</tr>
<tr>
<td><strong>Country</strong></td>
<td><strong>Israel</strong></td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
</tr>
</tbody>
</table>
| **Funding organisation** | CSO-MOH  
| **National contact persons** | Dr. Ayelet ZAMIR  
E-mail: ayelet.zamir@moh.gov.il |
| **National programme** | Medical Research Administration |
| **Funding commitment** | Up to 0.3 Mio € |
| **Anticipated number of fundable project partners** | Up to 2 |
| **Maximum funding per grant awarded to a project partner** | Up to 140,000 € (up to 600,000 NIS) per project. An additional 20,000 Euros (up to 100,000 NIS) will be granted if the Israeli researcher is the coordinator |
| **Eligibility of projects** | Bio-Medical research at large |
| **Eligibility of a partner as a beneficiary institution** | Position in a university, research center or hospital. Research authority must approve position prior to submission |
| **Eligibility of principal investigator or other research team member** | PI should hold a Ph.D., M.D., D.M.D. or equivalent degree and employed by an eligible institution. Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any single program. |
| **Eligibility of costs, types and their caps** | Personnel (students, technicians, applicants excluded); Animal, Materials and consumables; Travel (up to 10%); Institutional overhead 10%. No permanent equipment. |
| **National phase** | Prior to submission, researchers must submit to CSO-MOH an abstract approved by their research authority including detailed budget distribution. This is not the consortia abstract, but an abstract describing the activity of the Israeli researcher within the consortia. No submission of abstract can lead to disqualification of the whole application, as well as the consortium. Bioethics approvals, if applicable should be submitted with the application or within 4 months later. Submission of financial and scientific reports at the national level is required annually. |
| **Further guidance** | Please see detailed instruction at:  
<table>
<thead>
<tr>
<th>Country</th>
<th>ITALY</th>
</tr>
</thead>
</table>
| Funding organisation | Ministry of Health (Ministero della Salute)  
www.salute.gov.it |
| National contact persons | Dr. Gaetano GUGLIELMI  
Directorate General for Health Research and Innovation  
Ministry of Health – Ministero della Salute  
Viale Giorgio Ribotta,5  
00144 Rome, Italy  
Phone:+39 06 5994.3528  
E-mail: g.guglielmi@sanita.it  

Dr. Silvia PARADISI  
Directorate General for Health Research and Innovation  
Ministry of Health – Ministero della Salute  
Phone:+39 06 4990 6553  
E-mail: silvia.paradisi@iss.it |
| Funding commitment | € 3 Mio |
| Anticipated number of fundable project partners | 10 |
| Maximum funding per grant awarded to a project partner | € 300.000,00 |
| Eligibility of projects duration | Max 3 years |
| Eligibility of a partner as a beneficiary institution | Only Scientific Institutes for Research, Hospitalization and Health Care (IRCCS, Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati) are eligible.  
Non fundable: University, other research institutes, companies. |
| Eligibility of principal investigator or other research team member | Simultaneous participation in different transnational research calls funded by the Ministry of Health on the same year is not allowed to Italian Principal Investigators.  
In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to submission of the proposal. To this end, it is mandatory that the applicants fill out and return to the MoH a pre-eligibility check form (link), through IRCCS Scientific Directorate by using |
the WFR System, before submitting their proposals. It is strongly recommended that the completed form is returned at **least 10 working days before** the proposal submission deadline. Applicants will be sent a written notification in case of non-eligibility.

<table>
<thead>
<tr>
<th>Eligibility of costs, types and their caps</th>
<th>Direct Costs:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Personnel (only temporary contracts) (max 50%);</td>
</tr>
<tr>
<td></td>
<td>Consumables;</td>
</tr>
<tr>
<td></td>
<td>Animals;</td>
</tr>
<tr>
<td></td>
<td>Subcontracts (Max 20%);</td>
</tr>
<tr>
<td></td>
<td>Equipment (only on hire);</td>
</tr>
<tr>
<td></td>
<td>Travel (max 10%);</td>
</tr>
<tr>
<td></td>
<td>Publications (Max 1%).</td>
</tr>
<tr>
<td><strong>Indirect Costs:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overhead (max 10%);</td>
</tr>
<tr>
<td></td>
<td><strong>other indirect costs are not eligible</strong></td>
</tr>
</tbody>
</table>

<p>| National phase Further guidance | After the TRANSCAN-2 JTC 2017 peer review process has been completed and the final (scientific) ranking list has been established and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations, according to national regulations. Submission of annual scientific and financial reports at the national level are required according to the rules of the Ministry of Health. Further information on the rules of the Ministry of Health can be found at <a href="http://www.salute.gov.it">http://www.salute.gov.it</a>, section &quot;Ricerca Sanitaria&quot;, or requested to the national contact persons. |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding organisation</strong></td>
<td>Alliance Against Cancer (ACC)</td>
</tr>
<tr>
<td><strong>National contact persons</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Prof. Gennaro Ciliberto  
Tel +390659943412  
email gennaro.ciliberto@ifo.gov.it | | |
| Dr Maddalena Barba  
Tel. +390659943412  
email maddalena.barba@gmail.it | | |
<p>| <strong>National programme</strong> | Framework National Programme “Health Research” of the Italian Ministry of Health |
| <strong>Funding commitment</strong> | 0.300 M € |
| <strong>Anticipated number of fundable project partners</strong> | 1-2 |
| <strong>Maximum funding per grant awarded to a project partner</strong> | 0.150 M € |
| <strong>Eligibility of projects</strong> | Please refer to the call text |
| <strong>Eligibility of a partner as a beneficiary institution</strong> | Based on the D.Legis 229/99, eligible partners will be Hospitalization and Health Care Institutes, i.e., Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS, pubblici e private. The following will be not fundable: Universities, research institutions other than the aforementioned, companies. |
| <strong>Eligibility of principal investigator or other research team member</strong> | In full agreement with the procedures applied by the Italian Ministry of Health, Alliance Against Cancer will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. The eligibility check will be performed based on the use of a dedicated pre-eligibility check form (link) to be filled out before submitting the pre-proposals to the Joint Call Secretariat. Potential applicants will be requested to return this form in its completed and duly signed PDF version to the Direzione Generale (email address: <a href="mailto:dirgen@alleanzacontroilcancro.it">dirgen@alleanzacontroilcancro.it</a>) at least 10 working days before the pre-proposal submission deadline. A written notification will be sent to clarify the applicant eligibility status. |
| <strong>Eligibility of costs, types and their caps</strong> | Only costs generated over the lifetime of the project will be considered eligible. Personnel (only temporary contracts) (50%); Consumables; Animals; Subcontractors (max 20%); Equipment (only on hire); Travels (max 10%); Overheads (max 10%); Publications (max 1%); Travel expenses and subsistence allowances related to training activities of the projects. |
| <strong>For the research project as well as for the capacity building and training activities:</strong> | Once a definitive ranking list will be generated and endorsed by the Call Steering Committee, the coordinators and principal investigators of the projects granted for funding will enter the formal national negotiation (in agreement with the national regulation). Annual scientific and financial reports at the national level will be required. |
| <strong>National phase</strong> | Further details will be provided by the national contact persons upon request. |
| <strong>Further guidance</strong> | |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>Italy - Lombardy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>Regional Foundation for Biomedical Research (FRRB)</td>
</tr>
</tbody>
</table>
| National contact persons    | Mrs Carmen De Francesco  
Address: Via Taramelli 12, 20124 - Milano  
Tel: +39 02 67650170  
Email: carmen.defrancesco@frrb.it  
Dr. Paola Larghi, PhD  
Via Taramelli 12, 20124 - Milano  
Tel: +39 02 67650173  
Email: paola.larghi@frrb.it |
| Regional programme          | Regional Action Plan for the Biomedical Research – Year 2017 |
| Funding commitment          | 1.250 M € |
| Anticipated number of fundable project partners | 2-3 |
| Maximum funding per grant awarded to a project partner | 0.500 M € |
| Eligibility of projects     | Please refer to the Call Text |
| Eligibility of a partner as a beneficiary institution | Public or Private IRCCS (Italian Scientific Institutes for Health Research and Health Care), Health Care Providers (ASST), Universities, Research Institutes located in the Lombardy territory. It is COMPULSORY that at least one IRCCS (public or private) or ASST is partner of the submitted project proposal. Other types of organisation are eligible ONLY in partnership with the IRCCS and ASST.  
NB: Enterprises and for profit Organisation are NOT eligible |
| Eligibility of principal investigator or other research team member | In full agreement with the internal procedures, Regional Foundation for Biomedical Research (FRRB) will grant an eligibility clearance to the potential applicants prior to the submission of the pre-proposals. The eligibility check will be based on the use of dedicated forms (link) (also available on FRRB institutional web-site starting from the launch of the Joint Transnational Call) to be returned by email to FRRB's Contact Person duly completed and signed by the Principal Investigator at least 10 working days before the pre-proposal submission deadline. |
The eligibility status will be notified by written communication.

**Eligibility of costs, types and their caps**

<table>
<thead>
<tr>
<th>Cost Type</th>
<th>Eligibility Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>(in case of public IRCCS and ASST ONLY temporary contracts) (max 50% of direct costs)</td>
</tr>
<tr>
<td>Consumables and animals purchase, maintenance and breeding</td>
<td></td>
</tr>
<tr>
<td>Subcontractors</td>
<td>(max 20%)</td>
</tr>
<tr>
<td>Equipment</td>
<td>(on hire or eligible amortisation rate)</td>
</tr>
<tr>
<td>Travels</td>
<td>(Travel expenses and subsistence allowances related to training activities of the projects) (max 10%)</td>
</tr>
<tr>
<td>Overheads</td>
<td>(flat rate 20%, calculated on the basis of direct costs - Subcontracts are excluded from this calculation)</td>
</tr>
<tr>
<td>Publications</td>
<td>(max 5%)</td>
</tr>
</tbody>
</table>

According to its internal rules, FRRB will require the submission of a financial audit certificate together with the final report. This cost will be considered eligible up to a maximum of €8,000.

FRRB considers as eligible costs for “Capacity building activities” which covers travel and accommodation costs for exchanges programme envisaged inside the project and not already included in the Travels cost category.

**For the research project as well as for the capacity building and training activities:**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>National (regional) phase</td>
<td>Once a definitive ranking list will be generated and endorsed by the Call Steering Committee, the coordinators and principal investigators of the projects granted for funding will enter the formal national/regional negotiation (in agreement with the national regulation). Annual scientific and financial reports at the national/regional level will be required.</td>
</tr>
</tbody>
</table>

Further guidance

Administrative and financial guidelines will be provided by FRRB in due time to the contact persons of the funded organisations.
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th><strong>Latvia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding organisation</strong></td>
<td>Valsts izglītības attīstības aģentūra</td>
</tr>
</tbody>
</table>
| **National contact persons** | **Dr. Maija BUNDULE**  
Tel: +371 67785423  
E-mail: maija.bundule@viaa.gov.lv  
**Dr. Uldis BERKIS**  
Tel: +371 29472349  
E-mail: uldis.berkis@viaa.gov.lv |
| **National programme** | Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma Limitations and requirements of these provisions apply without exceptions. |
| **Funding commitment** | 420,000 € |
| **Anticipated number of fundable project partners** | 2 |
| **Maximum funding per grant awarded to a project partner** | Max 70,000/ year (for a 3-year project this will be 210,000 EUR grant) |
| **Eligibility of projects** | The projects should correspond to the priorities of the TRANSCAN Call. Duration of the project - up to 3 years. The activities must correspond to "research" according to Latvian Law on Scientific Activity. |
| **Eligibility of a partner as a beneficiary institution** | Legal bodies: universities, state research institutes, other research institutions: should be listed in the Latvian register of research institutions. Enterprises entered into the Latvian Commercial registry are eligible, assumed they are eligible to do the specific research and can prove possession of research resources in Latvia, and their main research is in Latvia. Limitations of EU legislation apply (R 651/2014) together with financial reporting requirements. |
| **Eligibility of principal investigator or other research team member** | Principal investigator – researcher holding a doctoral degree and experienced in the field related to the project thematic. Other research team members - researchers, physicians, technicians, assistants and supporting staff. |
| **Eligibility of costs, types and their caps** | Project eligible costs are as follows:  
**For the research project:**  
1. Personnel costs incl. taxes;  
2. Consumables; |
3. Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;
4. Equipment (only depreciation costs);
5. Replaceable and fully consumable during project elements of equipment, materials and animals;
6. Travels (according to travel plan);
Indirect costs (up to 25% of direct costs excluding subcontracting).

**For the capacity building and training activities:**
1. Short term training related to the project needs – covering possible only to direct travel costs.
Core activities cannot be subcontracted.

### National phase

No special national procedures in application phase
In the contract phase annual scientific and financial reports will be required. Final research project cost statement must be audited by a dedicated auditor. Ethics and regulatory permissions are responsibility of the consortium.
**Latvian legislation requires conclusion of Consortium Agreement in order Latvian partner to be fundable.**

### Further guidance

<table>
<thead>
<tr>
<th>Country</th>
<th>Luxembourg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisations</td>
<td>National Research Fund Luxembourg</td>
</tr>
</tbody>
</table>
| National contact persons | Frank Glod, PhD  
Head of Unit - Strategic Research Programmes  
Maison du Savoir  
2, avenue de l'Université  
L-4365 Esch-sur-Alzette  
Postal Address : B.P. 1777 I L-1017 Luxembourg  
T +352 261925-33  
frank.glod@fnr.lu |
| National programme | INTER |
| Funding commitment | 0.3 M€ |
| Anticipated number of fundable project partners | 1-2 |
| Maximum funding per grant awarded to a project partner | 0.3 M€ |
| Eligibility of projects | Please refer to the call text. |
| Eligibility of a partner as a beneficiary institution | Please refer to the terms and conditions of the FNR on the following website:  
https://www.fnr.lu/fnr-beneficiaries/ |
| Eligibility of costs, types and their caps | Salary-related costs  
Small equipment costs  
Travel  
Direct running and dissemination and knowledge exchange costs  
Overheads |
<p>| National phase | A summary of the submitted proposal will have to submitted also via the FNR grant management system |
| Further guidance | Applicants should contact the National Call Secretariat before application of a proposal |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>THE NETHERLANDS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding organisation</strong></td>
<td>Dutch Cancer Society (DCS / KWF Kankerbestrijding)</td>
</tr>
<tr>
<td><strong>National contact persons</strong></td>
<td>Dr. Miranda Wijdenes: tel: + 31-20-5700500; email: <a href="mailto:mwijdenes@kwf.nl">mwijdenes@kwf.nl</a></td>
</tr>
<tr>
<td><strong>National programme</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>Funding commitment</strong></td>
<td>€ 1 Mio</td>
</tr>
<tr>
<td><strong>Anticipated number of fundable project partners</strong></td>
<td>2 – 3</td>
</tr>
<tr>
<td><strong>Maximum funding per grant awarded to a project partner</strong></td>
<td>DCS does not have a maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget. However it is recommended to respect the available budget and anticipated number of fundable research groups mentioned above (including funding for capacity building and training activities).</td>
</tr>
<tr>
<td><strong>Eligibility of projects</strong></td>
<td>Please refer to the call text.</td>
</tr>
<tr>
<td><strong>Eligibility of a partner as a beneficiary institution</strong></td>
<td>Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a></td>
</tr>
<tr>
<td><strong>Eligibility of principal investigator or other research team member</strong></td>
<td>Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a></td>
</tr>
<tr>
<td><strong>Eligibility of costs, types and their caps</strong></td>
<td>Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a></td>
</tr>
<tr>
<td><strong>For the research project as well as for the capacity building and training activities:</strong></td>
<td>Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a> NB. Overhead costs are not eligible for funding.</td>
</tr>
<tr>
<td><strong>National phase Further guidance</strong></td>
<td>The official call announcement will be published on the KWF Kankerbestrijding <a href="#">website</a>; applicants are strongly advised to contact the national contact person</td>
</tr>
<tr>
<td>Country</td>
<td>POLAND</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
</tr>
<tr>
<td>Funding organisation</td>
<td>National Centre for Research and Development (NCBR) (<a href="http://www.ncbr.gov.pl">http://www.ncbr.gov.pl</a>)</td>
</tr>
</tbody>
</table>
| National contact persons | Dominika Mickiewicz  
Section for international programmes  
National Centre for Research and Development  
ul. Nowogrodzka 47a, 00-695 Warszawa, Poland  
+48 22 39 07 139  
dominika.mickiewicz@ncbr.gov.pl |
| National programme | National Scientific Research Programme (Krajowy Program Badań) |
| Funding commitment | 0.6 M € |
| Anticipated number of fundable project partners | 2 - 3 |
| Maximum funding per grant awarded to a project partner | The maximum cost should not exceed 0.25 M € for each Polish partner in the project. |
| Eligibility of projects | All proposals must be aligned with National regulations, inter alia:  
- The Act of 30 April 2010 on the National Centre for Research and Development (consolidated text: Journal of Laws of 2017, item 1447, as amended)  
- The Regulation of the Minister of Science and Higher Education of 25 February 2015 on criteria and rules on granting state aid and de minimis aid through the National Centre for Research and Development (Journal of Laws of 2015, item 299). |
| Eligibility of costs, types and their caps | The eligible costs shall be the following:  
1. personnel costs (researchers, technicians and other supporting staff to the extent employed on the research project);  
2. costs of instruments and equipment, technical knowledge and patents to the extent and for the period used for the research project. |
| Organization must be registered in Poland. | |
as for the capacity building and training activities:

- **research project**; if such instruments and equipment are not used for their full life for the research project, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice, shall be considered eligible;

- **costs for buildings and land**, to the extent and for the duration used for the research project; with regard to buildings, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice shall be considered eligible; for land, costs of commercial transfer or actually incurred capital costs shall be eligible;

- **cost of contractual research**, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national experts panel;

- **other operating costs** including costs of materials, supplies and similar products, training activities incurred directly as a result of the research activity;

- **additional overheads** incurred indirectly as a result of the research project; that costs cannot account for more than 25% of eligible project costs; That costs (6) are counted as a multiplication by percentage given above (called x%) and the rest of direct costs, excluding subcontracting (4); It means $6=(1+2+3+5)^*x\%$.

### National phase

#### Further guidance

Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list will be established.

### National funding rates

<table>
<thead>
<tr>
<th>Type of Research</th>
<th>Large Enterprises</th>
<th>Medium Enterprises</th>
<th>Small Enterprises</th>
<th>Universities and research organizations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fundamental/Basic Research</strong></td>
<td>Up to 100 %</td>
<td>Up to 100 %</td>
<td>Up to 100 %</td>
<td>Up to 100 %</td>
</tr>
<tr>
<td><strong>Industrial/Applied Research</strong></td>
<td>Up to 50+15 (max 65 %)</td>
<td>Up to 50+10+15 (max 75 %)</td>
<td>Up to 50+20+15 (max 80 %)</td>
<td>Up to 100 %</td>
</tr>
<tr>
<td><strong>Experimental development</strong></td>
<td>Up to 25+15 (max 40 %)</td>
<td>Up to 25+10+15 (max 50 %)</td>
<td>Up to 25+20+15 (max 60 %)</td>
<td>Up to 100 %</td>
</tr>
</tbody>
</table>

In any case only Fundamental/Basic Research, Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) is not eligible for funding as separate research tasks in the project schedule.
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th>Portugal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding organisation</strong></td>
<td>Foundation for Science and Technology (Fundação para a Ciência e a Tecnologia – FCT)</td>
</tr>
</tbody>
</table>
| **National contact persons** | Marta Abrantes  
+351 213 911596  
marta.abrantes@fct.pt |
| **National programme** | |
| **Funding commitment** | 0.100 Mio € |
| **Anticipated number of fundable project partners** | 1 |
| **Maximum funding per grant awarded to a project partner** | 100,000 € |
| **Eligibility of projects** | All proposals must be aligned with National regulations ([https://www.fct.pt/apoios/projectos/regulamentofundosnacionais.phtml.pt](https://www.fct.pt/apoios/projectos/regulamentofundosnacionais.phtml.pt)) |
| **Eligibility of a partner as a beneficiary institution** | National regulations apply. |
| **Eligibility of principal investigator or other research team member** | National regulations apply. |
| **Eligibility of costs, types and their caps** | For the research project as well as for the capacity building and training activities:  
National regulations apply. Capacity building is part of normal project activities; there is no dedicated budget to this item, it should be included in the other items of the budget. |
<p>| National phase | In the pre-proposal and in the full proposal phases no national application is needed, the electronic transnational application to the central TRANSCAN-2 Joint Call Secretariat is sufficient. Nevertheless, the Portuguese teams will need to send a statement of commitment (<a href="https://www.fct.pt/apoios/cooptrans/eranets/docs/Declaracao_Compromisso_FCT_Editavel.pdf">https://www.fct.pt/apoios/cooptrans/eranets/docs/Declaracao_Compromisso_FCT_Editavel.pdf</a>) to the National Contact Point at FCT, duly signed, dated and stamped by the Head of the Portuguese applicant organization and by the Principal Investigator, at the stage of pre-proposals. The national teams participating in the transnational projects that will be selected for funding by the TRANSCAN-2 Call Steering Committee will have to submit their application to the Foundation of Science and Technology (FCT), for management of the project. |</p>
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th>Slovak Republic</th>
</tr>
</thead>
</table>
| **Funding organisation** | Slovak Academy of Sciences  
http://www.sav.sk |
| **National contact persons** | Jan BARANCIK, PhD.  
Department for International Cooperation of SAS,  
Slovak Academy of Sciences, Štefánikova 49  
814 38 - Bratislava, Slovak Republic  
Tel: +421 2 5751 0137  
E-mail: barancik@up.upsav.sk  
  
Martin NOVAK, PhD.  
Department for International Cooperation of SAS,  
Slovak Academy of Sciences,  
Štefánikova 49  
814 38 - Bratislava, Slovak Republic  
Tel: +421 2 5751 0179  
E-mail: mnovak@up.upsav.sk |
| **National programme** | Research in the field of biological, medical and pharmaceutical sciences |
| **Funding commitment** | 0.21 Mio € (to be confirmed) |
| **Anticipated number of fundable project partners** | 1-2 |
| **Maximum funding per grant awarded to a project partner** | up to 105 000 €/per project for 3 year project period |
| **Eligibility of projects** | 3 year transnational projects with 3 or more eligible project consortium partners and from at least 3 different TRANSCAN joint transnational call 2011 funding countries  
Translational projects are encouraged |
| **Eligibility of a partner as a beneficiary institution** | Only research Institutes of the Slovak Academy of Sciences are eligible organisations for funding by SAS (up to 100%). Applicants from other Slovak R&D centres (universities and/or other organisations) have to cover the project costs from their own sources (letter of Commitment). In addition to this, the teams outside of SAS can be consortium members but not the coordinator of the consortium. |
| **Eligibility of principal investigator or other research team member** | Each researcher of the core research team of a project consortium Slovak partner (other than the Principal Investigator) must have a job contract with or a fellowship with such a Slovak project partner, lasting until the end of the project or beyond  
The principal Investigator of the research team of a project consortium Slovak partner must be a senior researcher having a job contract with such a project partner, lasting until the end of the granted project or beyond. |
| **Eligibility of costs, types and their caps** | Direct costs (DC) : Personnel (max. 15% of DC), Consumables, Equipment (max. 40% of DC) and Travel costs will be as eligible costs.  
Indirect costs (IC - overheads): max. 20 % of DC. Total eligible costs = DC + IC  
Training costs shall not be defined as a separate category, but included in other costs items.  
**National phase**
Submission of the proposal at a national level will be carried out once the international evaluation and the ranking list have been performed and endorsed by the Call steering committee (CSC) and the Slovak project partner has been informed by the project consortium coordinator and invited by SAS to submit the proposal to it. The Presidium of SAS makes the final decision concerning the approval of funding (according to internal rules of SAS).

**Further guidance**
- [http://www.sav.sk/](http://www.sav.sk/)
- 133 Act of February 19, 2002 on the Slovak Academy of Sciences,
- Financial rules for awarding SAS grants for research projects in frame of ERA.Net Programme for research institutes of SAS
- Principles of allocation of funds for the institutes of SAS to support projects in the field of international scientific cooperation
<table>
<thead>
<tr>
<th>Country</th>
<th>SPAIN</th>
</tr>
</thead>
</table>
| Funding organisation | Spanish Association Against Cancer Scientific Foundation (AECC FC)  
[www.aecc.es](http://www.aecc.es) |
| National contact persons | Marta Puyol  
Email: marta.puyol@aecc.es  
Tel: (+34) 913108207 |
[www.fundacioncientifica.aecc.es](http://www.fundacioncientifica.aecc.es) |
| Funding commitment | € 0.25 Mio |
| Anticipated number of fundable project partners | 2-3 research groups |
| Maximum funding per grant awarded to a project partner | • Up to 150,000 € per partner  
• Up to 200,000 € per coordinator |
| Eligibility of projects | Only 3-year projects |
| Eligibility of a partner as a beneficiary institution | | Coordinator | Partner |
| Hospitals, primary health care or public health settings of the Spanish National Health System (SNS)¹ | YES | YES |
| Public Cancer Research Centres (those working exclusively in the field of Cancer diseases) | YES | YES |
| Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS)² | YES | NO |
| CIBER or CIBERNED | YES | NO |
| In addition to the Spanish entities listed above we allow the following entities participation³ | | Coordinator | Partner |
| Universities | YES | YES |
| Research Performance Organizations recognized as such according to the Act 14/2011, of June 1st, of Science, Technology and Innovation, as well as the other ones hold by Public Administrations³ | YES | YES |

¹These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the Foundation’s Statutes may be submitted)³ Accredited according to the RD 339/2004, of February 27th (these institutions may manage research via a foundation regulated according to the Spanish Act 50/2002, of December 26th)  
³Please note that these entities can only participate if they apply together with Hospitals, primary health care or public health settings of the Spanish National Health System (SNS), Public Cancer Research
Centres, Accredited Health Research Institutes (Institutos de Investigación Sanitaria Acreditados, IIS), CIBER or CIBERNED, in the same proposal. **It is not allowed to apply independently.**

**NOTE:**
- Only one partner per beneficiary institution may be funded within the same proposal.
- SMEs and other private companies are encouraged to participate at their own cost, as subcontractors or funded by other sources including CDTI’s open calls for internationalization.

### Eligibility of principal investigator or other research team member

The Principal Investigator (PI) and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS.

**Excluded personnel as Principal Investigator (PI):**
- Those undergoing a postgraduate training in Health Specialization (MIR, FIR, QIR, BIR, PIR)
- Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts)
- Researchers contracted by a RETIC or a CONSOLIDER
- Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts)

**NOTE:**
- Only one proposal per partner is allowed.
- Researchers with ongoing TRANSCAN projects in 2019 cannot apply to the current call except if the applicant is the coordinator.
- There is no other incompatibility with AES 2018. Incompatibilities with other calls are subject to their respective specifications.

### Eligibility of costs, types and their caps

<table>
<thead>
<tr>
<th></th>
<th>Coordinator</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Up to 3-year, full-time or part-time contracts (only for additional personnel)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small Equipment</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Travel and Allowance</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Consumables</td>
<td>Not eligible (see ISCIII criteria for funding)</td>
<td></td>
</tr>
<tr>
<td>Subcontracting and other services</td>
<td>Not eligible (see ISCIII criteria for funding)</td>
<td></td>
</tr>
<tr>
<td>Overheads</td>
<td>Not eligible (see ISCIII criteria for funding)</td>
<td></td>
</tr>
</tbody>
</table>

### Special considerations

The AECC Scientific Foundation will co-fund the awarded research projects with the ISCIII on a cost-basis manner.

Any publication resulting from the granted projects must acknowledge “Award no. XX by ISCIII thorough AES 2018 and within the TRANSCAN framework” even after the end of the project.
<table>
<thead>
<tr>
<th>Country</th>
<th>SPAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>National Institute of Health Carlos III</td>
</tr>
<tr>
<td>National contact persons</td>
<td>Dori Campo  tel: +34 91 822 2489; email: <a href="mailto:doricampo@isciii.es">doricampo@isciii.es</a></td>
</tr>
<tr>
<td>Funding commitment</td>
<td>€ 0.25 Mio</td>
</tr>
<tr>
<td>Anticipated number of fundable project partners</td>
<td>2-3 research groups</td>
</tr>
</tbody>
</table>
| Maximum funding per grant awarded to a project partner | Up to 150,000 € per partner  
Up to 200,000 € per coordinator |
| Eligibility of projects | Only 3-year projects |
| Eligibility of a partner as a beneficiary institution | | | Coordinator | Partner |
| Hospitals, primary health care or public health settings of the Spanish National Health System (SNS)¹ | YES | YES |
| Public Cancer Research Centres (those working exclusively in the field of Cancer diseases) | YES | YES |
| Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS)² | YES | NO |
| CIBER or CIBERNED | YES | NO |

**In addition to the Spanish entities listed above we allow the following entities participation³**

| Universities | YES | YES |

¹These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the Foundation’s Statutes may be submitted)³ Accredited according to the RD 339/2004, of February 27th (these institutions may manage research via a foundation regulated according to the Spanish Act 50/2002, of December 26th) [Link](http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml).  
²Accredited according to the RD 339/2004, of February 27th (these institutions may manage research via a foundation regulated according to the Spanish Act 50/2002, of December 26th) [Link](http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml).  
³Please note that these entities can only participate if they apply together with Hospitals, primary health care or public health settings of the Spanish National Health System (SNS), Public Cancer Research Centres, Accredited Health Research Institutes (Institutos de Investigación Sanitaria Acreditados, IIS), CIBER or CIBERNED, in the same proposal. **It is not allowed to apply independently.**
Only one partner per beneficiary institution may be funded within the same proposal.
- SMEs and other private companies are encouraged to participate at their own cost, as subcontractors or funded by other sources including CDTI’s open calls for internationalization

Eligibility of principal investigator or other research team member

The Principal Investigator (PI) and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS.

Excluded personnel as Principal Investigator (PI):
- Those undergoing a postgraduate training in Health Specialization (MIR, FIR, QIR, BIR, PIR)
- Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts)
- Researchers contracted by a RETIC or a CONSOLIDER
- Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts)

NOTE:
- Only one proposal per partner is allowed.
- Researchers with ongoing TRANSCAN projects in 2019 cannot apply to the current call except if the applicant is the coordinator.
- There is no other incompatibility with AES 2018. Incompatibilities with other calls are subject to their respective specifications

Eligibility of costs, types and their caps

<table>
<thead>
<tr>
<th>Personnel</th>
<th>Coordinator</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 3-year, full-time or part-time contracts (only for additional personnel)</td>
<td>Total cost per annual full-time contract:</td>
<td>Not eligible</td>
</tr>
<tr>
<td>Excluded: Students and fellowships</td>
<td>• Technical expert, higher degree:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>29,500 €</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Technical expert, medium degree:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24,500 €</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Technical expert, FP II:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20,500 €</td>
<td></td>
</tr>
<tr>
<td>Small Equipment</td>
<td>Up to 40,000 €</td>
<td>Up to 20,000 €</td>
</tr>
<tr>
<td>Travel and Allowance</td>
<td>Up to 9,000 €</td>
<td>Up to 4,500 €</td>
</tr>
<tr>
<td>Consumables</td>
<td>Up to 100% of direct cost</td>
<td></td>
</tr>
<tr>
<td>Subcontracting and other services</td>
<td>Up to 50% of direct cost</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Private (bio)companies and SMEs included</td>
<td></td>
</tr>
<tr>
<td>Overheads</td>
<td>Up to 21% of direct cost, included in the maximum funding per grant awarded to a partner</td>
<td></td>
</tr>
</tbody>
</table>

National phase

National applications will be required from applicants officially invited by ISCIII. Any publication resulting from the granted projects must acknowledge “Award no. XX by ISCIII thorough AES 2018 and within the TRANSCAN framework” even after the end of the project.
<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Spain / Asturias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT) <a href="http://www.ficyt.es">http://www.ficyt.es</a></td>
</tr>
</tbody>
</table>
| Regional contact persons | Ms. Inés REY HIDALGO  
Tel: +34 985 20 74 34  
E-mail: inesrey@ficyt.es |
| Regional programme | Regional Programme for funding Science, Technology and Innovation |
| Funding commitment | € 0.2 Mio. |
| Anticipated number of fundable project partners | 2 TRANSCAN-2 transnational project partners |
| Maximum funding per grant awarded to a project partner | Only one grant per fundable project partner:  
- Up to 150,000 € per project coordinator (up to 200,000 € per project for the whole Asturian part funded by the Regional Ministry in case more than one Asturian partner participates in the same proposal and an Asturian eligible institution coordinates the project consortium);  
- Up to 100,000 € per project partner (up to 150,000 € per project for the whole Asturian part funded by the Regional Ministry in case more than one Asturian partner participates in the same proposal, and both takes part as partners in the consortium).  
Funding by FICYT is subject to the approval of the relevant annual appropriations by the Regional Parliament in Asturias |
| Eligibility of projects | Applicants must fulfill the eligibility requirements of the TRANSCAN-2 international call.  
- Minimum duration of the project: 12 months for industrial research / 9 months for experimental development.  
- Maximum duration of the project: 36 months.  
- Industry must demonstrate incentive effect of the aid. |
| Eligibility of a partner as a beneficiary institution | Applications must be submitted by entities located in Asturias or, in case of companies, with a production center in Asturias. |
| Eligibility of principal investigator or other research team member | There will be a contact person taking part in the project to act as intermediary with the funding agency. |
| Eligibility of costs, types and their caps | Expenses can only be committed and invoices charged with dates of each year in which the Asturian aid is granted  
- New staff: researchers hired to work in the project once it has started.  
- Own staff: only for companies / only those employees dedicated to the research project submitted to TRANSCAN-2 international call  
- Equipments: depreciation costs.  
- Consumables. |
| Subcontracts: up to 50% of the direct costs of the regional project.  
| Other costs: travels, accommodation costs and allowances (only for staff appearing in the Personnel area of the proposal that directly takes part in the project); patenting costs; audit costs.  
| Overheads: according to the regulation of the regional call. |

### Regional phase

The submission of the proposal at regional level will be carried out once the international evaluation and the ranking list have been performed and endorsed by the Call Steering Committee (CSC) and the Spanish project partner IP has been informed by the project consortium coordinator.

### Further guidance

All applicants must comply with all the Regulations applicable to public funding at European, National and Regional level, and with all those Regulations indicated in the Regional Regulatory Bases and calls. Link to the Regulatory Bases: [http://www.ficyt.es/pri/docs/BasesReguladorasTranscan.pdf](http://www.ficyt.es/pri/docs/BasesReguladorasTranscan.pdf)
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th>Taiwan</th>
</tr>
</thead>
</table>
| **Funding organisation** | Ministry of Science and Technology  
| **National contact persons** | Dr. Louis CHEN  
Ministry of Science and Technology (Taiwan)  
Tel:+886-2-2737-7959  
E-mail: ymchen@most.gov.tw |
| **National programme** | Medical Research Administration |
| **Funding commitment** | 0.5 Mio. € |
| **Anticipated number of fundable project partners** | 2-3 |
| **Maximum funding per grant awarded to a project partner** | NTD 3Mio/Year (roughly €70,000/Year) |
| **Eligibility of projects** | The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied. |
| **Eligibility of a partner as a beneficiary institution** | All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the Ministry of Science and Technology as beneficiary institution. |
| **Eligibility of principal investigator or other research team member** | The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied. |
| **Eligibility of costs, types and their caps** | Personnel, Consumables, Hosting expenses for foreign researchers, Travel expenses for international destinations-joint research & overseas studies |
| **National phase** | No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the Ministry of Science and Technology of your submission to the TRANSCAN-2 joint transnational call via email, together with your application as an attachment.  
A formal proposal must be submitted electronically via the Ministry’s web submission portal together with an official missive sent from your institution, submission should be done after the joint TRANSCAN JTC 2014 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee. The submitted proposal will formally be granted by the Ministry of Science and Technology after an administrative and scientific processing. |
<p>| <strong>Further guidance</strong> | Refer to the official announcement by the Ministry of Science and Technology for more information (<a href="http://www.most.gov.tw/">http://www.most.gov.tw/</a>) |</p>
<table>
<thead>
<tr>
<th><strong>Country</strong></th>
<th>TURKEY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding organisation</strong></td>
<td>The Scientific and Technological Research Council of Turkey (TÜBİTAK) <a href="http://tubitak.gov.tr/en">http://tubitak.gov.tr/en</a></td>
</tr>
<tr>
<td><strong>National contact persons</strong></td>
<td>A. Özge Gözay +90312 2981893 <a href="mailto:ncphealth@tubitak.gov.tr">ncphealth@tubitak.gov.tr</a></td>
</tr>
<tr>
<td><strong>Funding commitment</strong></td>
<td>300,000 €</td>
</tr>
<tr>
<td><strong>Anticipated number of fundable project partners</strong></td>
<td>2 projects</td>
</tr>
<tr>
<td><strong>Maximum funding per grant awarded to a project partner</strong></td>
<td>Up to 720,000 TL (app 160,000 €) per partner excluding overhead (Two times the regular budget of a national 1001 project)</td>
</tr>
<tr>
<td><strong>Eligibility of projects</strong></td>
<td>Maximum 36 months</td>
</tr>
<tr>
<td><strong>Eligibility of a partner as a beneficiary institution</strong></td>
<td>The funding is granted to Principal Investigators from universities, public or private sector. The PI is subject to eligibility check.</td>
</tr>
</tbody>
</table>
| **Eligibility of principal investigator or other research team member** | **Project Manager, Researchers and Advisors:**  
- University personnel should have a PhD degree.  
- Those working in a public institution or a private corporation should have an undergraduate degree.  
- Except advisors, the project manager and researchers should reside and work in Turkey.  
- A researcher should have a contribution of at least 10% of the project workload.  
- An advisor is allowed if the project requires special expertise on a specific subject. The number of advisors in a project is limited to the number of specific subjects in the project. The role of advisor in the project should be explained in detail in the project proposal.  
**NOTE:** University rectors and vice rectors, deans, head of academy/institute, surgeons general, general secretaries, general managers, state department heads and members of the executive committee/advisory board of TÜBİTAK groups cannot be the project manager in any project if they are working in those positions as of the application date. However, they can be researchers in at most two projects. |
| **Eligibility of costs, types and their caps** | **Personnel**  
Up to 3-year, full-time or part-time contracts (only for additional personnel)  
Excluded: PI | **Coordinator**  
The costs can not be declared in the project budget, but provided by TÜBİTAK as an extra grant. (Proje Teşvik İkramiyesi) | **Partner**  
PI is excluded. Other researchers are eligible for funding. |
<p>| <strong>Small Equipment</strong> | Must be used for the project |</p>
<table>
<thead>
<tr>
<th>Travel and Allowance</th>
<th>Up to 25,000 TL, app 7000 €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumables</td>
<td>Up to 100% of direct costs</td>
</tr>
<tr>
<td>Subcontracting and other</td>
<td>Eligible</td>
</tr>
<tr>
<td>services</td>
<td></td>
</tr>
<tr>
<td>Overheads</td>
<td>Not eligible, provided as an</td>
</tr>
<tr>
<td>extra</td>
<td></td>
</tr>
</tbody>
</table>

**For the research project as well as for the capacity building and training activities:**

Capacity building activities are not eligible for funding from TUBITAK. Short visits to other labs should be spent from the project’s travel budget.

**National phase Further guidance**

Participants from Turkey should also submit their proposals in Turkish to TUBITAK electronically via [ardeb-pbs.tubitak.gov.tr](http://ardeb-pbs.tubitak.gov.tr) by 12\(^{th}\) of February for pre-proposals and no later than 5\(^{th}\) of June for the full proposal stage. The signed hard copy should be sent via regular mail within one month after both deadlines.